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ABSTRACT 
The Effect of HIV-exposure on Cellular Immune Responses to EPI Vaccines 
and Antigens 
Background 
Immunization against vaccine-preventable infections is essential to reducing childhood 
morbidity and mortality. The immaturity and tolerogenicity of the immune system of infants 
renders them susceptible to infectious diseases and makes induction of protective immunity via 
vaccines a challenge. HIV-exposed infants are HIV uninfected and born to HIV-infected mothers 
and have increased morbidity and mortality of unknown aetiology. We hypothesise that T cells 
of HIV-exposed uninfected (HEU) infants have impaired proliferative ability and cytokine 
production in response to vaccine antigens than HIV unexposed (HU) infants. 
Methods 
We recruited HEU and HU infants at birth and followed them until 14 weeks of life. Between 1-
3mL whole blood was collected from 46 participants in each group of infants  at 6 and 14 weeks 
of age and stimulated with
 
Mycobacterium bovis bacillus Calmette-Guérin (BCG), Tetanus 
toxoid (TT), Bordetella pertussis (BP) antigens, a negative control (medium alone) and a positive 
control, Staphylococcal enterotoxin B (SEB). Cells were fixed and upon thawing permeabilized 
and stained for intracellular INF-γ, IL-2, IL-13 and IL-17 cytokines (ICS) and Ki67, CD3 and 
CD8 with fluorescence-conjugated antibodies. Multiparameter flow cytometry (BD LSR 
Fortessa) was used to measure expression of these markers. Data analysis was performed by 
FlowJo V9.4, GraphPad prism V5, STATA V11, Pestle V1.7 and Spice V5.22 software 
packages. 
Results 
HIV-exposure was found to enhance the proliferative responses to BCG vaccination and SEB, 
but had no effect on BP and TT responses. After adjusting for potential confounders, HEU 
infants had higher CD4+ T cell proliferation to BCG through time from 6 to 14 weeks of life. 
HIV-exposed uninfected infants possessed significantly lower frequencies of CD8-expressing 
IL-17 and IL-13 compared with HU infants in response to BCG at 14 weeks of life. Proportions 
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infants irrespective of the time points or antigen stimulation. Generally, HIV-exposed infants had 
similar BCG, BP and TT vaccine-induced intracellular cytokine responses over time from 6 to 14 
weeks of life.  
Conclusion 
The findings may have important implications for the optimal timing and vaccination strategies 
for HIV-exposed infants and careful immunological evaluation of future HIV and TB vaccines in 
this group.  
HEU infants had significantly lower frequencies of IL-13 production by CD8+ T cells compared 
to HU infants in response to BCG at 6 and 14 weeks of life, and of IL-17 production by CD8+ T 
cells in response to BCG at 14 weeks of age. The presence of these cytokine producing cells at a 
significantly lower frequency may be sub-optimal to protect HEU infants from infections and 
other viral infections as a significantly higher frequency of these infants presented with flu like 
symptoms compared to their un-exposed counterparts. However, HEU infants produced a 
significantly higher frequency of IL-13 and IL-17 by CD4+ T cells at 14 weeks of life in 
response to BCG.   
No significant differences were observed between HEU versus HU infants frequency of cytokine 
production by CD4+ and CD8+ T cells following BP and TT stimulation at 14 weeks of life, 
illustrating equal levels of protection between the groups of infants. HIV exposure was a major 
predictor of IL-17 production by CD8+ T cells in response to BCG longitudinally through time 
to 14 weeks after adjusting for other confounders presented by the cohort in the multivariate 
model, this shows that CD8 lymphocytes may be primed in utero in HEU infants.  
HIV-exposure can alter immune responses to some antigens at 14 weeks (lower CD8+ cytokine 
production to BCG) but not 6 and HIV-exposure has no effect on frequency of cytokine 
production by CD4+ and CD8+ T cells following BP and TT stimulation at 14 weeks of life. The 
proportion of vaccine antigen stimulated CD4+ and CD8+ T cells that responded to in vitro 
culture were significantly less polyfunctional in the HEU compared to the HU infants at both 
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1.1 The immune system (General) 
 
The immune system is an organization of cells and molecules with specialized roles to defend 
against infections. There are two different types of responses to invading microbes; the innate 
response which is rapid and non-specific (Delves, 2000), and the acquired or adaptive response, 
which is specific, and takes several days to weeks to develop, has immunological memory and 
provides the host with a state of protective immunity against re-infection with the same pathogen 
(Janeway, 2001).  
Functionally, the innate immune response is the body’s first line of defence and involves 
phagocytic cells (neutrophils, monocytes, macrophages) and immune factors (complement, 
cytokines and acute phase proteins), cells that release inflammatory mediators (basophils, mast 
cells, and eosinophils), natural killer (NK) cells, natural killer T cells (NK T-cells) and Gamma 
Delta T-cells (γ  T-cells) ((Delves, 2000)(Beck et al., 1996). Another major cellular component 
of the innate immunity is the interdigitating dendritic cell (e.g. langerhans’ cells in the skin) that 
continuously endocytose extracellular antigens and become activated as antigen-presenting cells 
(APC) when pattern-recognition receptors (PRR) on their surface recognise distinctive 
pathogens-associated molecular patterns (PAMPs) on the surface of microorganisms(Medzhitov 
et al., 1997).  
Despite these innate immune mechanisms, pathogens often pass these defences and adaptive 
immunity is then required. Adaptive immunity is further divided into the humoral and cell 
mediated immune systems that involve the proliferation of antigen-specific B and T cells after 
antigenic peptides are displayed to specific surface receptors for binding. While B cells secrete 
immunoglobulins for antigen-specific antibodies in charge of eliminating extracellular pathogens 
and molecules (toxins, bacteria), T cells take care of intracellular microorganisms i.e. cell 
mediated immunity (CMI) (viruses, mycobacteria, some fungi, protozoa or other facultative 
intracellular pathogens) and also provide help for B cells to produce antibodies (Beck et al., 
1996).  
During CMI responses, cells that can destroy other cells become activated, with their destructive 
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responses may also destroy cells making mutated forms of normal molecules, as in some 
cancers(Anthony, 2008).  
 
1.1.1 Innate response to pathogens 
Innate immunity covers many areas of host defense against pathogenic microbes, including the 
recognition of PAMPs(Janeway et al., 2002), which enable the immune system to distinguish 
between infectious (non-self) and non-infectious (self) molecular structures by its specific PRRs. 
PRRs are highly diverse; some recognise PAMPs directly, while others (e.g. Toll like receptors 
[TLR]) recognise the product generated by PAMPs (e.g. bacterial CpG-ODN)(Mogensen, 2009). 
However, the nature of the PRR ligand determines the receptor for signalling the presence of the 
specific pathogen. Cellular PRRs are expressed on effector cells including professional APC and 
cells on the surface of epithelia and some expressed intracellularly(Inohara et al., 2005).  
PRRs directly induce innate effector mechanisms following recognition of a PRR ligand, for 
example, viral nucleic acids that are recognised by cells in which they replicate. This interaction 
induces expression of inflammatory cytokines and chemokines by the cell (Medzhitov et al., 
1997). This lead to the maturation, differentiation, and proliferation of multiple immune cells, 
including B and T lymphocytes after the antigen is presented to them as peptides by major 
histocompatibility complex (MHC) molecules. Including, NK cells, monocytes, macrophages, 
and dendritic cells (DCs). Together, these cells secrete cytokines and chemokines that create a 
pro-inflammatory [interleukin-1beta (IL-1β), IL-6, IL-18,  and tumor necrosis factor-alpha 
(TNF-α)] and T helper 1 (Th1)-biased (IFN-ϒ  and IL-12) immune milieu (Bendelac, 
1997)(Klinman et al., 2004). 
     
1.1.2 T cell-mediated immunity  
T and B cells predominantly mediate the adaptive arm of immunity.  
The cell-mediated compartment of the immune system involves the professional APC notably by 
DCs, macrophages and B cells, that up-regulate costimulatory molecules on their surface for 
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MHC molecules on the surface of APC in form of short peptides to T cells after processing (or 
proteolytic cleavage).  
There are many classes of MHC molecules, two of which are involved in classical T cell; MHC 
classes I and II that present the peptides to T-cell receptors (TcRs) on the surface of cytotoxic 
(CTL) and helper (Th) T lymphocytes respectively, thus stimulating an immune response 
specific to that peptide antigen(Fraser, 2011). DCs are particularly efficient at initiating 
(priming) immune responses for which immunologic memory has not been established, by 
activating naïve T cells to expand into a population of antigen-specific effector T cells(Delves, 
2000). MHC class I molecules bearing peptides activate CTLs which kill infected target cells, 
whereas, MHC class II molecules bearing peptides from pathogens in intracellular vesicles 
activate either T helper-type 1 (Th1) or T helper-type 2 (Th2) cells. Each naïve CD4 T cell has 
the potential to differentiate into either of the functionally distinct T helper effector cell subsets, 
Th1 or Th2, Th17 and T regulatory cells (Szabo et al., 2003).  
CD4+ T helper cells are important mediators of adaptive cellular immune responses. Based on 
their cytokine production profile, they have until recently been classified into Th1 and Th2 
subsets. Th1 effectors produce predominantly Interferon-gamma (IFN-γ) and IL-2 and regulate 
cellular immunity against intracellular infections, whereas Th2 cells produce predominantly 
Interleukin (IL)-4, IL-5 and IL-13 and mediate humoral immunity activating the naïve antigen-
specific B cells to produce IgM antibodies against parasitic infections. Moreover, Th2 cells can 
subsequently stimulate the production of different immunoglobulin isotypes, including IgA and 
IgE, as well as neutralizing and/or weakly opsonizing subtypes of IgG(Chu et al., 2000).  
 
Recently, a CD4+ Th cell subset known as T helper 17 (Th17) cells was described(Weaver et al., 
2006)(Lin, 2011). Th17 cells produce the cytokines IL-17A (IL-17) and IL-17F, as well as the 
cytokines IL-21, and IL-22. This new Th cell lineage fills in some of the missing gaps in host 
immunity not fully explained by the Th1/Th2 paradigm(Wozniak et al., 2006)(Lin et al., 2011).  
 
Though humoral and cell-mediated immunity have many distinctive features, they are not 
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as receptors for killing target cells. Activation of complement system by antigen-antibody 
complexes gives rise to chemotactic peptides which help in assembling the cell types required for 
a cell-mediated response(Rus et al., 2005). In addition, the immune system regulates its function 
by several ways including regulatory T cells often measured by levels of IL-10 and 
CD4+CD25+FoxP3+ regulatory T cells. These cells are present to dampen immune responses to 
micro organisms(Jiang et al., 2006).  
During T cell development and maturation, cells pass through three different subsets; naïve, 
central and effector memory subsets. These subsets can be differentiated using flow cytometry 
by identifying several receptors on T cells for example CD45RA/RO, and CCR7. CD45RA/RO 
consists of different isoforms of a protein tyrosine phosphatase expressed at different stages of 
differentiations that regulate Src (sarc) kinases required for T cell receptor signal transduction. 
CCR7 is a chemokine receptor that regulates homing and trafficking of cells to secondary 
lymphoid organs. (Sallusto et al., 1999)(Janeway, 2008). 
Immunological memory is defined as the ability of the immune system to respond more rapidly 
and effectively to pathogens that have been previously encountered. Naïve T cell subsets are 
characterized by CD45RA+CCR7+, central memory (CM) by CD45RA-CCR7+ and the effector 
memory (EM) CD45RA-CCR7- (Sallusto et al., 1999)(Janeway, 2008). These subsets have 
different functional properties from localization, proliferation capacities, cytokine expression and 
cytotoxic functions. While naïve and CM T cells are found predominantly in the lymph nodes, 
the EM T cells are in the skin and mucosa (sites of infection) ready to fight pathogens. The 
proliferation capacity after antigenic stimulation of CM T cells is highest compared to naïve T 
cells and lowest in EM T cells that are more specialized to fight pathogens(Sallusto et al., 
1999)(Janeway, 2008). Based on expression of cytotoxic molecules, high frequencies of EM T 
cells expressed perforin, granzyme A and granzym B compared to CM T cells, while naïve T 
cells expressed none of the cytotoxic molecules(Takata et al., 2006)(Romero et al., 2007). The 
cytokine secretion profiles of these cell sub sets vary, naïve and CM T cells secrete more IL-2 
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1.1.3 Development of the immune system 
Evidence suggests that foetal and adult T cells arise from different pluripotent haematopoietic 
stem cells (HSC) present at different stages of development. This suggests that the foetal T cell 
HSC lineage is biased towards immune tolerance, an observation that offers a mechanistic 
explanation for the tolerogenic properties of the developing foetus and for variable degrees of 
immune responsiveness at birth(Mold et al., 2012).  
 
HSC are early precursor cells which give rise to all the blood cell types including the myeloid 
lineage (monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, and 
dendritic cells) and lymphoid lineages (T cells, B cells and NK cells)(Moss, 2001)(Abramson et 
al., 1977).  The HSC are found within the bone marrow (of the femurs, humeri, hip, ribs, sternum 
and other bones).  Therefore, the bone marrow is the primary site and origin of lymphocytes. 
Lymphoid stem cells differentiate into three major populations of mature lymphocytes: T cells, B 
cells and NK cells.  These subsets can be distinguished by their surface phenotypes(Chaplin, 
2003). T cells are defined by their unique cell surface expression of the T cell receptor (TCR) 
while B cells are phenotypically defined by their production of the immunoglobulin antigen-
binding proteins(Chaplin, 2006). 
 
1.2 Immunity in the neonate (Innate and adaptive responses) 
The immune system of neonates is said to be relatively underdeveloped and depends largely on 
maternal antibodies transmitted in-utero and in some cases post partum. The complexity of the 
immune system of infants renders them susceptible to infectious diseases and makes induction of 
protective immunity via vaccines a challenge(Ota et al., 2012). Neonatal innate, humoral, and 
cellular immunity is different to that of adults(Jaspan et al., 2007)(Jaspan, et al., 2006). At the 
single-cell level, neonatal innate cells have been found to be generally less capable of producing 
multiple cytokines simultaneously, i.e. less polyfunctional(Kollmann et al., 2012). Infants can 
produce small amounts of immunoglobulin G (IgG) during the first few months of life following 
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Maternal IgG and IgA may reach infants through the placenta and breast milk, respectively. 
These immunoglobulins may interfere with the infant's humoral response to certain 
vaccines(Lambert et al., 2005). Although T cell immunity is less affected by maternal antibody, 
certain aspects of T cell immunity of the neonate are immature. Neonates are thought to 
predominantly make Th2 cytokines, which include; interleukins (IL) IL-4, IL-5, and IL-13, 
important for B cell function and control of extracellular pathogens and helminths(Lambert et 
al., 2005). In contrast, Th1 secrete interferons-gamma (IFN- ), IL-2 and tumour necrosis factors 
(TNF), which are important for control of intracellular pathogens such as viruses(Jaythoon et al., 
2000).  
Infant macaques have higher fractions of CD4+CD25+CD127+
low
FoxP3+ T regulatory cells in 
the peripheral blood and in lymphoid tissues, and these cells showed greater in vitro suppressive 
activity on a per cell basis(Connor et al., 2007). Contrary to the thinking that neonatal immunity 
is immature, evidence suggests that the development of CD4+CD25
high
FoxP3+ T regulatory cells 
that suppress fetal antimaternal immunity persist at least until early adulthood(Mold et al., 2009). 
These cells represent a form of antigen-specific tolerance in humans, induced in utero and 
probably active in regulating immune responses after birth(Mold et al., 2009).  
Little is known about the neonate’s and infant’s ability to mount Th17 responses in humans. 
Most of the data on IL-17 has been from mouse models. It has been shown in mice that 
activation of innate immune cells through TLR4 supports the direction and induction of Th1 and 
Th-17 cells, which mediate protective cellular immunity to Bordetella pertussis(Higgins et al., 
2012). IL-10 signalling blockade during BCG vaccination of mice resulted in a sustained Th17 
(IL-17) response that increased protection against Mycobacterium tuberculosis infection(Pitt et 
al., 2012). Further, BCG vaccination induces lung IL-17- expressing CD4+ T cells in mice. The 
IL-17 expressing CD4+ T cells are said to trigger the production of chemokines that recruit 
CD4+ T cells producing interferon- , which ultimately restrict bacterial growth(Khader et al., 
2007).  
However, in humans, delaying BCG vaccination from birth to 4.5 months of life lowers IL-17 
and other responses after vaccination but produces a comparable Mycobacterial response at 9 
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Maternal factors and in utero exposure to various microorganisms may play a role in neonatal 
immunity. Hepatitis C virus (HCV)-exposed neonates have a relatively suppressed immune 
activation, proinflammatory marker production, however, they have an increased production 
capacity for IFN-  (Babik et al., 2011). This suggests that when exposed to HCV in utero, the 
balance between suppressive and pro-inflammatory responses is altered. Also, exposure to 
malarial antigens in utero caused a predominant regulatory response in newborns born to 
mothers with ongoing chronic placental malaria (PM), while those with resolved infection 
produced both regulatory and inflammatory responses(Flanagan et al., 2010).  
 
1.2.1 Breastfeeding and immune responses in infants 
Maternal antibody protects infants against many infectious diseases and maternal immunization 
augment this protection in young infant against diseases(Englund et al., 1998)(JACOB et al., 
1977). Moreover, breast milk reduces the frequency and severity of gastrointestinal and 
respiratory infections in infants(ELLESTAD-SAYED, 1979)(Downham et al., 1976) and in 
addition to these specific antibodies to pathogens and other factors within breast milk enhance 
the immune responses of the neonatal immune system(Van Rie et al., 2005).  
 
However, there is limited data on effect of HIV-exposure and more data is needed on the effect 
of breastfeeding on T-cell mediated immune responses to neonatal vaccines. Exclusive 
breastfeeding enhances vaccine responses in infants(Rennels, 1996)(Pabst et al., 1988). Some 
studies demonstrated a trend toward a decreased seroresponsiveness in breastfed compared with 
non-breastfed children(Moon et al., 2010). The inhibitory influence of maternal antibodies on 
infants’ immune responses to vaccines (e.g. whole cell pertussis) is thought to be B-cell specific 
and leaves the infant T-cell responses largely unaffected(Van Rie et al., 2005). In general, the 
evidence that breastfeeding enhances the functional protection of the neonatal immune system 
against pathogens surpasses that for lack of enhancement, however, more evidence for this is 
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  1.3 Cytokines 
Cytokines are small, nonstructural proteins with molecular weights ranging from 8 to 40,000 
Daltons (d) that nearly all nucleated cells are capable of synthesizing and, in turn, responding 
to(Dinarello, 2000). Cells that can respond to cytokines include; the same cell that secreted 
cytokine (autocrine), a nearby cell (paracrine), or a distant cell reached through the circulation 
(endocrine)(Bowers, 2012). Cytokines can be grouped according to function; (a) Mediators and 
regulators of Natural Immunity (pro-inflammatory/innate) [e.g. Tumor Necrosis Factor alpha 
(TNF-α), Interleukin-1 (IL-1), IL-6 and IL-12 (b) Adaptive cytokines {Th1 [Interferon-gamma 
(IFN- ) and IL-2], Th2 [IL-4 and IL-13] and Th17 [IL-17] (c) Mediators and regulators of 
specific immunity (regulatory) [IL-10](Bowers, 2012). Below is the description of the various 
cytokines that we investigated this dissertation and their interactions. 
  
1.3.1 Adaptive cytokines 
1.3.1.1 T helper type 1 (Th1) cytokines 
Interferons (IFN) are best known for interfering with viral replication(Isaacs, 1989), hence 
termed virus inhibitory proteins. The major source of IFN is mitogen activated T lymphocytes. 
Three types of IFN have been described; IFN-alpha (α) and IFN-beta (β) that belong to the type I 
super family and IFN–gamma (γ) that belong to the type II family of interferons. T lymphocytes 
and NK cells are the main sources of IFN-γ(DeMaeyer, 1988). It is induced naturally by antigens 
to which T cells have been pre-sensitized. However, non-specific T cell activators (PMA-
Ionomycin) in vitro can also induce IFN-γ synthesis in T cells and NK cells(Hardy, 
1989)(Perussia et al., 1992).  
IFN-γ production increases with age in infants(Van Rie et al., 2006). Neonates have limited 
capacity to produce IFN-γ and reduced cell-mediated immune responses involving cytotoxicity 
against intracellular pathogens(Siegrist, 2007)(Ota et al., 2012).  
IL-2 stimulates resting T cells and supports long term growth, activation, and proliferation of T 
cells (Smith, 1988).  IL-2 is also a potent modulator of T and NK cell function, and it is the most 
extensively investigated cytokine to date. It also is used as a vaccine adjuvant to boost Th1 
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is mature T cells (both T helper and cytotoxic) within 4-12 hours following activation by antigen 
or mitogen(Smith et al., 1979). Vaccination at birth with BCG has been shown to significantly 
enhance Th1 responses to mycobacterial antigens(Burl et al., 2012).  
1.3.1.2 T helper type 2 (Th2) cytokines 
IL-13 is a very important cytokine that possesses a number of anti-inflammatory and 
immunomodulatory activities. IL-13 is a member of the Th2 group of cytokines together with IL-
4 and IL-5. Neonates produce predominantly Th2 responses instead of the much needed Th1 
responses against intracellular pathogens(Jaspan et al., 2007)(Siegrist, 2007). In addition, 
African neonates mount significantly higher Th2 cytokines compared to Europeans, possibly 
reflecting continuous presence (stimulations) of antigens that preferentially drive Th2 
responses(Wilfing et al., 2001). 
1.3.1.3 T helper type 17 (Th17) cytokines 
Members of the Th17 cytokines include IL-17A (IL-17) and IL-17F, as well as the cytokines IL-
21, and IL-22 (Wozniak et al., 2006)(Lin et al., 2011). Th17 cells may influence vaccine-induced 
memory immune responses mostly to bacterial antigens. IL-17 has been shown to populate the 
lungs, the primary site of Mycobacteria tuberculosis infections, and in turn recruit IFN-γ 
producing antigen-specific T cells persistent in the central lymphoid organs(Lin et al., 2011). T 
helper cells that mostly IL-17 or IL-22 have been described, and are known for their involvement 
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Figure 1.1: Functional CD4+ T cell subsets. Naïve CD4+ T cells differentiate into functional subsets under the 
influence of different combinations of cytokines and acquire stable cytokine expression profiles and functions. 
Effector CD4+ T cells may differentiate into T helper 1 (Th1), Th17, Th22 and Th2 cells expressing predominantly 
interferon-gamma (IFN-γ), interleukin-17 (IL-17), IL-22, and IL-4 respectively. Regulatory T cell subsets with 
immunosuppressive function are classified into T regulatory (Treg) cells producing IL-10 and CD4+CD25+ Foxp3+ 
cells that express transforming growth factor-b (TGF-b) [Source: Modified from (Sala et al., 2012)].  
 
1.4 HIV prevalence and maternal-infant HIV transmission 
Human Immunodeficiency virus (HIV) causes acquired Immunodeficiency syndrome (AIDS) 
and is one of the world’s most serious health and development challenges(UNAIDS, 
2012)(UNAIDS, 2011a). Currently, approximately 34 million people have died of AIDS-related 
causes since the first cases were reported in 1981 (The Henry J. Kaiser Family 
Foundation/UNAIDS, 2012)(UNAIDS, 2011b).  Almost all cases of HIV (97%) reside in low- 
and middle-income countries, particularly in sub-Saharan Africa (SSA)(The Henry J. Kaiser 
Family Foundation/UNAIDS, 2012).  
Over 3.5 million women of childbearing age are infected annually with HIV in SSA and large 
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Figure 1.2: Adult HIV Prevalence Rate (Ages 15–49), [Source:  (UNAIDS, 2010)(UNAIDS, 2009)] 
 
Paediatric HIV-1 infection is still a major pandemic, it is estimated that there are more than 2 
million children  infected with HIV-1 worldwide and that more than 1800 new HIV infections 
are transmitted daily from mothers to infants(UNAIDS/WHO, 2006). Transmission rate can be 
reduced to as low as 1-2% with the use of HAART or dual therapy(UNAIDS, 2012).  
 
1.5 The HIV-exposed uninfected (HEU) infant 
HIV-exposed but uninfected (HEU) infants are HIV-uninfected infants born to HIV-infected 
mothers(Jones et al., 2011). An estimated two million infants are exposed in utero to HIV of 
which an approximately 1.5 million are HIV uninfected. Moreover, due to the high maternal HIV 
prevalence mostly in SSA, and the introduction of prophylactic interventions to prevent vertical 
transmission rate of HIV coupled with the successful and ever improving prevention of mother-
to-child transmission (PMTCT) programs in many parts of the world(Mbori-ngacha et al., 2001), 
this leaves a growing proportion of HEU infants in regions where antenatal HIV prevalence is 
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1.5.1 Immunological abnormalities in HEU infants 
There are several reports of increase morbidity and mortality in HEU compared to the HIV-
unexposed (HU) infants(Epalza et al., 2011)(Kuhn et al., 2006)(Mussi-pinhata, 2006)(Marinda et 
al., 2007). Maternal immunosuppression due HIV infection tends to have adverse influence on 
the health of infants in addition to the risks of vertical HIV transmission(Kuhn et al., 2006).  
However, Zambian HIV exposed infants who remained uninfected after perinatal or early 
breastfeeding-related HIV exposure were of high risk of mortality and morbidity (pneumonia 
and/or sepsis) during the first few months of life regardless of their maternal disease stage or 
Socioeconomic status(Kuhn et al., 2006).  
Skin/mucous membrane infections and respiratory tract 
infections are common infections observed in HEU 
infants more often than HIV-unexposed infants(Mussi-
pinhata, 2006). Also, the incidence of Group B 
Streptococcal infection is significantly higher in HEU 
than in the un-exposed infants(Epalza, 2010).  
Immunological abnormalities caused by HIV exposure in infants born to HIV infected mothers 
are still to be defined(Mazzola et al., 2011). There are data documenting different responses to 
vaccine immunogens(Van Rie et al., 2006)(Jones, 2011)(Mazzola et al., 2011), and an increased 
risk of Pneumocystis jeroveci pneumonia, an opportunistic infection, (Marinda et al., 2007)  in 
HEU infants.  
HEU infants have Increased immune activation, possibly as a result of in utero exposure to HIV 
antigens and/or antigens related to other infections in HIV-infected mothers(Rich et al., 1997). 
Also, elevated levels of pro-inflammatory cytokines are present in HEU infants(Hygino et al., 
2008). Both immune activation and a proinflammatory cytokine profile is a major hallmark of 
HIV-infection and reported to correlate with many immune functional disturbances(Davenport et 
al., 2007)(Lieberman et al., 2010)(Pw, 2007).  
Finally, the immunological characteristics of very young HEU infants in SSA may be different to 
elsewhere in the developed world. To improve the morbidity of this immunologically vulnerable 
Figure 1.3: Pneumocystis jeroveci pneumonia in 
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group of infants, we need to understand the nature of their immune responsiveness to determine 
optimal vaccination and disease prevention strategies. More information is needed on the 
influence of intrauterine HIV exposure on cellular immune responses to mycobacterial and other 
antigens. 
1.5.2 Specific (acquired) immune responses in HEU Infants 
1.5.2.1 Antibody production in HEU infants  
Humoral immunity refers to antibody production and the accessory processes that accompany it, 
including Th2 activation and cytokine production, germinal centre formation and isotype 
switching, affinity maturation and memory cell generation(Rao, 2010). It also refers to the 
effector functions of antibody, which include pathogen and toxin neutralization, classical 
complement activation, antibody‐dependent cell‐mediated cytotoxicity (ADCC) and opsonisation 
and consequently phagocytosis and pathogen elimination(Nyland, 2009).  
More information about vaccine protective response for infants born to HIV-infected mothers 
still needs to be known. A study by Abramczuk et al., found that although HEU infants had 
protective titers for diphtheria and tetanus, their geometric mean anti-tetanus titers were lower 
than those of the HU infants(Abramczuk et al., 2011). Jones et al. (2011) demonstrated that HEU 
infants have lower specific antibody to tetanus and pertussis at birth, but robust responses 
following vaccination(Jones et al., 2011). This may be due to decreased quality or quantity of 
passively acquired maternal antibody. 
1.5.2.2 Cellular immune responses in HEU infants   
There are few data on the cellular immune response to vaccines in HEU, except for BCG. Bacille 
Calmette Guerin (BCG), a live attenuated Mycobacterium bovis vaccine, is almost universally 
given in SSA, where the brunt of the global paediatric HIV burden is concentrated(Hesseling et 
al., 2009). BCG is usually given at birth; its coverage worldwide is estimated at over 100 million 
doses per year, resulting in vaccination of 75% of infants born in 2002. In HIV-uninfected 
children, BCG is safe, efficacious and cost-effective against disseminated tuberculosis(Trunz et 
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BCG can elicit potent type 1 responses and effective CTL responses in infants when given at 
birth(Ota et al., 2012), although these type I responses may not be the correlate of vaccine-
induced protection. We do not know, however, how efficacious BCG is in HEU infants, although 
some evidence suggests that it may not be as immunogenic as in HU infants(Rie et al., 
2006)(Mazzola et al., 2011). In a study by Mazzola et al, the level of IFN-  produced in response 
to BCG increased with age in HEU infants. But at an early age, HEU infants produced less IFN-  
and TNF-α in response to BCG than HIV-unexposed infants suggesting there may be defects in 
immune responses(Mazzola et al., 2011).  
 
1.6 Vaccines and super antigens 
A vaccine is a preparation of a weakened or killed pathogen, such as a bacterium or virus, or of a 
portion of the pathogen’s structure or DNA that upon administration stimulates an immune 
response against the pathogen but is incapable of causing severe infection(Griffin et al.,  
2002)(Siegrist, 2008). Diseases caused by bacteria and some other pathogens can be prevented 
by vaccines licensed for use in several parts of the world(CDC, 2005). Hence, vaccines are an 
important part of disease prevention and control(Griffin et al., 2002).  
Vaccines developed thus far can be classified as follows; live attenuated vaccines, inactivated 
vaccines, subunit vaccines, toxoid vaccines, conjugate vaccines, virus-like particles, DNA 
vaccines and/or recombinant vector vaccines(The US department of health and human services). 
The problem with pure recombinant or synthetic antigens used in modern day vaccines is that 
they are generally far less immunogenic than older style live or killed whole organism vaccines 
which are in turn often more risky. This has lead to the use of immunological agents (adjuvants) 
that enhance immune responses to a vaccine but are not immunogenic on their own(Petrovsky et 
al., 2004).  
For a successful assessment of immune response to various vaccine antigens using in vitro 
assays, super antigens [e.g. staphylococcal enterotoxin B (SEB)] are often used as positive 
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act through widespread activation of certain Vβ TCRs and therefore are also interesting 
mechanisms to assess when evaluating immune responses in HEU infants. 
1.6.1 Vaccination 
The Expanded Programme on Immunization (EPI) was launched in 1974 and less than 5% of the 
world's children were immunized during their first year of life against 6 killer diseases in the 
same year; polio, diphtheria, tuberculosis, pertussis (whooping cough), measles and 
tetanus(UNICF/WHO, 2011). Today, immunization is been carried out effectively throughout 
the world, with some vaccines been prioritized in some areas where the disease burden is of 
major public health concern(CDC, 2005). Below is the EPI vaccination schedule used in South 
Africa (Table 1.1).  
 
Table 1.1: The EPI vaccination schedule used in South Africa;(1) BCG given at birth, (2) DTaP-IPV/Hib primed 
at 6 weeks, first, second boosters at 10, 14 weeks and third booster at 18 months of life and further at 6 and 12 years 
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1.6.1.1 Bacillus Calmette-Guérin (BCG) 
 After 13 years and 230 sub-cultures, in 1921, Calmette and Guerin together announced the 
discovery of a new strain of bovine tubercle bacilli which grew luxuriantly, was completely 
avirulent in animals and cause antibody production against tuberculosis, and showed no change 
in virulence if grown on standard egg based medium(Rajasekaran, 1961). BCG vaccine is the 
only vaccine currently available for immunization against tuberculosis (TB) infections and has 
been used since the 1920s. During this time numerous sub-strains have evolved from the original 
strain and have been used for vaccine production. Not surprisingly, the diversity of sub-strains, 
manufacturing processes, route of administrations, immunization schedules and levels of 
exposure to environmental mycobacteria and virulent Mycobacterium tuberculosis infection can 
cause variation in the immunogenicity of the vaccine(WHO, 2004).  
 
BCG is a live attenuated strain of Mycobacterium bovis, is almost universally given in sub-
Saharan African countries where the brunt of the global burden of paediatric infection including 
tuberculosis and HIV-1 is concentrated(Hesseling et al., 2009)(Organon, 2009). BCG 
vaccination has been part of the EPI since 1974, with coverage in infants exceeding 80%. The 
vaccine’s safety record after more than 4 billion administrations is as impressive as its low cost 
of US$0.10-0.20 per dose of product(Kaufmann et al., 2010). BCG vaccination is usually given 
at birth or in the perinatal period. In 2002, an estimated 75% of the 130 million children born 
worldwide were vaccinated with BCG(Hesseling et al., 2009). BCG has consistent efficacy for 
the prevention of tuberculosis meningitis and miliary tuberculosis in young children without HIV 
infection, but affords only variable and incomplete protection against pulmonary TB at any 
age(CDC, 2011)(WHO, 2009)(Trunz et al., 2006).  
 
1.6.1.2 acellular Bordetella Pertussis (aBP) 
Pertussis, or whooping cough, is an acute infectious disease caused by the bacterium Bordetella 
pertussis. Outbreaks of pertussis were first described in the 16th century, and the organism was 
first isolated in 1906(Gebhart, 1980)(States, 2008). Pertussis was one of the most common 
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States. Before the availability of pertussis vaccine in the 1940s, more than 200,000 cases of 
pertussis were reported annually. Since the widespread use of vaccine began, incidence has 
decreased more than 80%(Mooi et al., 2009)(States, 2008). Two forms of vaccines have been 
used (i) Whole-cell pertussis vaccine (wP) and (ii) acellular Pertussis vaccine (aP). The wP 
vaccine is composed of a suspension of formalin-inactivated Bordetella pertussis cells. It was 
developed in the 1930s and used widely in clinical practice by the mid-1940s(Mooi et al., 2001).  
Whole-cell Pertussis vaccine is 70%-90% effective in preventing serious pertussis disease. 
However, its protection decreased with time, resulting in little or no protection 5 to 10 years 
following the last dose. Local reactions such as redness, swelling, and pain at the injection site 
occurred following up to half of doses of whole-cell DTP vaccines. Fever and other systemic 
events were also common (seizures) (CDC, 2005)(Demirjian et al., 2009). This further raised 
concerns about its safety and led to the development of more purified (acellular) Pertussis 
vaccines that are associated with a lower frequency of adverse reactions.  
 
Acellular Pertussis vaccines are subunit vaccines that contain purified, inactivated components of 
Bordetella pertussis cells(Sato, 1999). Several acellular Pertussis vaccines have been developed 
for different age groups; these contain different Pertussis components in varying concentrations 
which include; the paediatric formulation (DTaP) often available in combination with other 
antigens [Infanrix hexa™ (DTaP-hepB-IPV-Hib); Infanrix-IPV™ (DTaP-IPV); Infanrix Penta™ 
(DTaP-hepB-IPV)] and the adolescent and adult formulation (dTap) of which four types are 
available containing reduced Pertussis antigen content in comparison to the vaccines for young 
children [Boostrix™ (dTap) and Boostrix-IPV™ (dTap -IPV), and Adacel™ (dTap) and Adacel 
Polio™ (dTap-IPV) (available since 2005)](NCIRS, 2009). Pertussis vaccine is available on the 
EPI schedule in many countries for children at 6, 10 and 14 weeks and at 18 months of 
age(Gebhart, 1980). An adolescent booster dose is available via school-based programs at 12-17 
years of age which vary by countries(CDPH, 2010)(NCIRS, 2009).  
1.6.1.3 Tetanus toxoid (TT) 
Tetanus is a deadly infectious disease for which immunization is available in EPI schedules of 
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Tetanus results from infection with Clostridium tetani, a commensal bacterium in the gut of 
humans and domestic animals which is found also in soil. It is not the presence of the bacteria 
which causes disease, but the toxins that are produced by the bacteria under anaerobic 
conditions(CDC, 2005). These toxins can be spread through the blood vessels and finally affect 
the nervous system causing tetanic muscle contraction and pain. The condition is extremely 
painful and potentially lethal(Aventis Pasteur, 1989)(Gaublomme, 2007).  
Immunization against tetanus is carried out by the administration of DTaP in infants and dTap in 
adults, both containing Tetanus toxoid with aluminium hydroxide as an adjuvant, and the vaccine 
is available in combination with other antigens as well as alone. The immunization schedule is 
similar to that of pertussis as they are administered in conjunction(CDC, 2012)(Gaublomme, 
2007). Following routine use of tetanus toxoid in the United States, the occurrence of tetanus 
decreased dramatically from 560 reported cases in 1974 to an average of 50-100 cases reported 
annually from the mid 1970s through the late 1990s. Neonatal tetanus occurs among infants born 
under unhygienic conditions to inadequately vaccinated mothers. Vaccinated mothers confer 
protection to their infants through transplacental transfer of maternal antibody(Sanofi Pasteur, 
1974).  
 
1.6.2 Superantigens [Staphylococcal enterotoxin b (SEB)] 
Superantigens are bacterial proteins that bind to the external portion of MHC class II and interact 
with restricted but large number of Vβ TCR’s, so that a single superantigen can activate up to 
20% or more of the total T cells in the body. In contrast, conventional antigenic peptides bind 
only to a subset of MHC molecules and to a very small fraction of the huge array of TCRs, 
thereby activating only a very small fraction of the total pool of T cells(Chaplin, 2006). 
Superantigens bind directly to the MHC molecule outside of the antigen-binding groove, and to 
TCR proteins outside of their antigen-MHC binding site without proteolytic processing(Chaplin, 
2010)(Fraser, 2011) (Figure 1.4). Superantigens cause non-specific activation of T-cells resulting 
in polyclonal T cell activation and massive cytokine release. For example, the toxic shock 
syndrome toxin-1 (TSST-1) produced by Staphylococcus aureus binds to and activates all T cells 
with TCRs using the Vβ2 and Vβ5.1 chains(Chaplin, 2003)(Chaplin, 2010). It is important to 
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are the most potent known activators of the immune system. Some member of Sags include 
toxins of Staphylococcus aureus and Streptococcus pyogenes (Fraser, 2011).  
At least one of the Superantigens, staphylococcal enterotoxin B (SEB), also binds to the 
costimulatory molecule CD28, suggesting that a much larger and potentially more stable 
complex is formed at the immunological synapse than was previously thought(Rajagopalan et 
al., 2002)(Fraser, 2011). SEB is the most extensively used and investigated superantigen today. 
It is unknown if HIV-exposure affects the responsiveness to Sags. HIV-exposure as well as 
infection may affect responses to Superantigens. Following SEB stimulation, HIV-infected 
children on HAART had significantly lower IL-2+ CD8 T cells and IFN-g+ CD4 T cells 
compared to the control uninfected infants(Mccloskey et al., 2004).  
 
 
Figure 1.4: The superantigen Theory (source:http://www.mcb.uct.ac.za/cann/335/AIDSI.html) 
 
1.7 Aims and objectives of the thesis  
We aim to evaluate the cellular immune responses to certain EPI vaccines as well as SEB in 
HEU versus HU infants. To this end we have two specific aims: 
(1) To compare CD4+ and CD8+ T cell proliferative responses to vaccines and SEB in HEU 
versus HU infants and to evaluate the evolution of the T cell proliferation to BCG and SEB from 
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(2) To compare the quality and breadth of CD4+ and CD8+ T cell intracellular cytokine 
production to vaccines and SEB in HEU versus HU infants and to evaluate the evolution of 
cytokine production to BCG and SEB from 6 to 14 weeks of life.  
  
Rationale 
(i) There are few studies comparing the proliferative ability of HEU infants’ lymphocytes in 
response to any vaccination to HU infant’s lymphocytes. 
(ii)  No study comparing the intracellular cytokine response to tetanus and pertussis 
vaccination between HEU and HU infants. 
(iii) Understanding the immune responses of  HIV-exposed infants ill help with design of 
neonatal HIV vaccines and other vaccines for this vulnerable group of infants 
In this study we will look at the cellular immune responses to vaccines critical for providing 
protection for infants with the ultimate goal to design interventions to improve the health of HEU 
infants, and to inform the design of a neonatal HIV vaccine. 
 
Hypothesis  
Generally, we hypothesise that HEU infants have less proliferation and less cytokine production 
by T-cells to vaccine antigens compared to HU infants. 
 
1.7.1 Specific objectives 
Specific objective 1 
To compare CD4+ and CD8+ T cell proliferative responses to BCG, BP and TT vaccinations and 
SEB in HEU versus HU infants and to evaluate the evolution of the T cell proliferation to BCG 
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Hypothesis 
HEU infants have lower lymphoproliferative ability at 6 and 14 weeks of life in response to 
vaccination [i.e. BCG administered at birth, Pertussis and Tetanus toxoid vaccine at 6 and 10 
weeks] and SEB. 
Specific objective 2 
To compare the quality and breadth of total CD4+ and CD8+ T cell intracellular cytokine 
production to BCG, BP and TT vaccine and SEB antigen in HEU versus HU infants and to 
evaluate the evolution of cytokine production to BCG and SEB from 6 to 14 weeks of life. 
Hypothesis 
HIV-exposed uninfected infants express lower quantity and breadth of cytokine producing cell 
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2.1 Study design 
This was an observational cohort study. 
The primary outcome measure was proliferation in response to Bacille Calmette Guerin (BCG), 
tetanus toxoid (TT), Bordetella pertussis (BP) and Staphylococcal enterotoxin B (SEB) between 
HIV-exposed uninfected (HEU) and HIV-unexposed (HU) infants at 6 and 14 weeks of age. The 
sample size and power calculations were based on the comparison of the primary outcome 
measure in an independent cohort i.e. the median number of CD4+ki67+ frequency in the HEU 
infants in response to BCG vaccination at birth measured at 8 weeks of age. This sample size 
(n=46) allowed an 80% power to detect a 10% difference in the frequency of CD4+ki67+ 
cells (2-tailed test at p=0.05).  
2.1.1 Participants and blood collection 
This was a longitudinal observational study of 46 HEU and an equal number of HU infants. 
Cellular immune responses were compared in whole blood of 6-week and 14-weeks old HEU 
infants to their unexposed counterparts after 6 days of incubation. Infants were recruited for two 
large studies conducted by Dr Heather Jaspan: 
Group 1. HIV-exposed uninfected (HEU) infants were studied to evaluate the effects of 
delaying BCG vaccination at either birth or given at 8 weeks of age. 46 infants who were 
randomised to the early BCG arm (BCG adminisered at 2-3 days after birth) were included in the 
current study. Infants were enrolled at birth, and followed-up at 2-3 days, 2 weeks, 6, 8, and 14 
weeks from February 2010 to June 2012.  
Group 2. HIV-unexposed infants (HU) were recruited at birth for an observational infant 
feeding study from June 2011 to August 2012. Forty six of these infants were used as controls 
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2.1.2 Recruitment of participants 
Both studies were recruited in Khayelitsha Site B, Western Cape, South Africa and consent 
forms were provided in English, Xhosa and Afrikaans. Consent for both studies included vaccine 
responses and was obtaineded from the mother in her preferred language and according to Good 
Clinical Practice guidelines. Questionnaires were similar for both cohorts. 
Study setting 
Khayelitsha site B is an informal settlement with an antenatal HIV prevalence of 30.1% in 
2011(City of Cape Town, 2011). It has good existing research capacity for prospective studies 
and ongoing recruitment and with established prevention of mother-to-child transmission 
(PMTCT) and pediatric antiretroviral (ARV) clinics. All deliveries at Site B are vaginal. 
BCG and oral polio vaccine (oPV) are routinely given at birth. Since April 2009, infants receive 
three doses of Diphtheria-Tetanus-aPertussis(DaPT)-iPV/Hib, Hepatitis B, Rotavirus (RV), and 
pneumococcal conjugate (PCV7) vaccinations at 6, 10 and 14 weeks of age (DOH, 2009) (See 
table 1.1).  
Since HIV infected infants have a high risk of BCG adverse events, in 2007 WHO  made HIV 
infection a full contraindication for BCG vaccination(WHO-SAGE, 2007). BCG was 
administered to HEU infants at a median age of two days (either at day 2 or 3 after birth) after 
HIV infection was ruled out. HIV-infected infants were not BCG vaccinated and referred 
immediately for antiretrovirals. BCG was administered at the morning after delivery for HU 
infants. 
2.1.3 Exclusion criteria and HIV testing 
For both groups of infants, ineligibility was based on the following; 
1. Mother was not willing and able to give consent 
2. Baby weighed less than 2.4 kg 
3. Baby was not healthy (presented with sepsis/ convulsions/ asphyxia/ severe respiratory 
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4. Mother or anyone in her house had TB or a cough for longer than two weeks, and the 
baby was then refered for isoniazid therapy(INH) 
5. Mother was planning to move away from Khayelitsha in the next 4 months 
6. Prematurity (i.e. <36 weeks) 
7. Mother was younger than 18 years 
 
Additionally for the HIV-exposed infants, eligibility was based on the following; 
8. Mother’s HIV test in pregnancy was positive 
9. Infant tested HIV DNA PCR negative either at 2-3 days or later at 6 weeks after birth 
 
And for the HIV-unexposed infants, eligibility is based on the following; 
1. Mother’s HIV test in pregnancy was negative 
HIV testing 
For the HIV-exposed infants, blood collection for HIV DNA PCR testing was done at birth and 
six weeks of age.  
2.2 Characteristics of the cohort  
We compared the characteristics of 46 HEU versus the 46 HU infants. Among all the parameters 
recorded, the birth weight (p=0.009), exclusive breast feeding (EBF) at birth (p<0.0001), the age 
at which BCG was given (p<0.001), and percentage morbidity (p<0.0001) were significantly 
different between HIV-exposed uninfected (HEU) and HIV-unexposed (HU) infants (Table 2.1).  
The median and the interquatile range (IQR) birth weight of the HEU versus HU infants [i.e. 3.1 
(2.8-3.4) Kg versus 3.3 (3.1-3.6) Kg] and the percentage (%) of infants exclusively breastfed 
(EBF) at birth between HEU versus HU infants [i.e. 23.8% versus 100%] were significantly 
lower in the HEU compared to HU infants. However, by 6 weeks and 14 weeks, the weight of 
the HEU was not significantly different to the HU infants, and the proportion of EBF infants was 
also not significantly different between the two groups of infants. The median and the IQR age at 
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overall percentage morbidity in HEU versus HU infants [i.e. Skin rash (30.9% versus 2.2%), 
Runny nose (35.7% versus 0%) and cough/fever (26.2% versus 13.0%)] were significantly 
higher in the HEU compared to the HU infants. The age in days at the 6- and 14-week visits, as 
well as the gestational age of the HEU infants was not significantly different to the HU infants 
(Table 2.1).   
Based on the exclusion criteria, mothers were not recruited if they were younger than 18 years. 
No information was taken based on parity of the mothers..There was little information collected 
on the socioeconomic status. Housing, electricity, and running water data was collected the HEU 
infant’s mothers, 31.4% lived in brick/formal structures, 60.8% in shacks, and a small proportion 
about 7.8% that stayed in any other form of housing not mentioned. There was no information on 
HU infant’s mothers. This is one of the limitations of the study. However, we believe they would 
be similar based on a recent cross-sectional study we performed.  
Table 2.1: Characteristics of the cohort between HEU versus HU infants at 6 and 14 weeks of life; the read outs 
for each parameter is indicated as medians and interquatile ranges (IQR) as well as in percentages (%) and p-values 
with red fonts illustrate parameters that were significantly different between HEU vs. HU infant groups i.e. p-
values<0.05, statistical significance was obtained using **Rank sum, *Chi square or 
$








Median birth weight (Kg)  (IQR) 3.3 (3.1-3.6) 3.1 (2.8-3.4) 0.009** 
Median weight at 6 weeks (Kg) (IQR) 4.9 (4.6-5.2) 4.8 (4.2-5.2) 0.097** 
Median weight at 14 weeks (Kg) (IQR) 6.6 (6.0-6.9) 6.6 (6.2-7.2) 0.596** 
Exclusive breastfed (EBF) at birth (%) 100% 23.8% <0.001
$
 
Exclusive breastfed (EBF) at 6 weeks (%) 39.5% 26.2% 0.191* 
Exclusive breastfed (EBF) at 14 weeks (%) 26.5% 24.3% 0.835* 
Median age at BCG given in days (IQR) 0 (0-1) 3 (2-4) <0.001** 
Median age at 6 weeks visit in days (IQR) 43.5 (43-48) 43 (42-44) 0.254** 
Median age at 14 weeks visit in days (IQR) 100 (98-112) 106 (98-113) 0.078** 
Median gestation age in weeks (IQR) 39 (38-40) 39 (37-40) 0.205** 
Morbidity (%) (6 Wks): - Skin rash 






















Chapter 2: Cohort characteristics   28 
 
2.3 Discussion 
The results show that HIV-exposed infants have lower median birth weight than HU infants 
(p<0.001) and also an overall increase in morbidity (p<0.001), emphasizing the vulnerability of 
HEU infants. There were some other differences evident in the cohort noted when analyzing the 
data and interpreting the results. Some of these, including birth breastfeeding practices and birth 
weight, would need to be accounted for as possible confounders when interpreting results.  
Data collection on morbidity and mortality were almost identical in the two cohorts.  Both 
groups of infants were recruited in the same community, presented to the same exposure and 
followed up similarly through the four seasons of the year in South Africa. 
Finally, Zambian HEU infants who remained uninfected after perinatal or early breastfeeding-
related HIV exposure were of high risk of mortality and morbidity during the first few months of 
life regardless of their maternal disease stage or Socioeconomic status(Kuhn et al., 2006). It is 
important to note that, maternal viral loads at delivery for the HEU infant’s mothers were not 
measured as it is not routine to collect baseline viral lo ds and most mothers in our study were 
not diagnosed during pregnancy. No information was taken on antiretroviral regimens placed for 
PMTCT at the time of delivery. However, at the time the study was performed, SA PMTCT 
guidelines recommended dual therapy for women with CD4 above 200 cells/mm
3
, and HAART 
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3.1 Materials and methods 
Based on the main aim of this dissertation; to evaluate cellular immune responses to EPI 
vaccines as well as SEB in HEU versus HU infants, we employed several techniques to achieve 
our goal. The overall process involved two assays: 
1. Whole blood assay (WBA)  ant its importance 
Optimized antigen concentrations were used. It has been shown that, it is important for whole 
blood to be incubated at 37
0
C with antigens as soon as possible after collection(Hanekom et al., 
2004). The WBA allowed immediate incubation of blood with antigens that would need to be 
processed (e.g. BCG and whole cell pertussis), and hence, produce optimal results(Soares et al., 
2010)(Soares et al., 2013). Table 3.1 below shows studies that have looked at cellular immune 
responses in HEU infants to date. Optimal antigen concentrations for WBA may significantly 
differ from that used in PBMC-based assays. Whole bacterial antigens, recombinant vaccinia 
virus-based antigens, proteins, and peptide antigens have been used successfully in the 
WBA(Hanekom et al., 2004)(Remick, 1999). 
Table 3.1: Published studies assessing vaccine cellular immune responses in HIV-exposed 
uninfected (HEU) infants 
1 = 7 day whole blood assay 
2 = 12 hour whole blood assay  
 a = ELISA 
 b = Flow cytometry 
 
Parameters Study Design Vaccine type Infant age Assay Proliferation/Cytokine 
Mazzola et al., 
2011  
Cross-sectional BCG 6.1mths -
26.3mths 




Rie et al., 2006  Longitudinal BCG Birth - wk6 WBA
1
 ND/IFN-Ƴ a 
Mansoor et al., 
2010 
Longitudinal BCG 3mth - 9mth WBA
2






Cross-sectional BCG Cord blood CBMC CD4+,CD8+/IL-2, IL-4, 
IL-7, IL-10, IL- 12, TNF-α 
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2. Flow cytometry [Proliferation and intracellular cytokine staining assay (ICS)] 
Conventional T cell (CD4 and CD8) that have the αβ T cell receptor (TCR) were the cells of 
interest. Using the WBA, antigen presenting cells (APC) would present the antigens in vitro 
to T cells via the MHC-peptide complex. Optimum stimulation of T cell was aided by other 
signals mediated by membrane receptors; B7.1/7.2 on APC and CD28 on T cells, 
endogenous IL-2 to it receptor on T cells, as well as other pro-inflammatory cytokines (IL-6 
and IL-12) by APC. These would lead to signal transduction by the CD3 complex and 
proliferation of T cells and further cytokine production(Janeway, 2008). Table 3.2 below 
shows the available methods to measure antigen specific responses and their importance. 
Also, non-conventional T cells [gamma-delta (Ƴ ) and Natural killer (NK) T cells] would 
also be present in whole blood. They are a minority of the peripheral CD3+ T cell population 
and with limited TCR usage(Janeway, 2008). Ƴ  T cells can recognize non-peptide antigens 
such as microbial metabolites and phosphor-antigens via their Ƴ  TCR directly(Bonneville et 
al., 2010), and NK T cells recognize glycolipids via their simi-invarian (Vα14-Jα18) TCR 
presented by the CD1d molecule on APC(Kaer, 2005)(Godfrey et al., 2004). NK T cells can 
act directly and indirectly to modulate function of other cell types. They directly activate 
lytic function by NK cells via IFN-Ƴ  production; indirectly activate proliferation, lytic 
function and cytokine production by CD4 and CD8 T cells via direct activation of dendritic 
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Table 3.2: Available methods to measure antigen specific responses, their pros and cons 
 
3.1.1 Whole blood assay (WBA)  
Between 1-3mL whole blood was collected from the two groups of infants at 6 and 14 weeks of 
age into a heparinised tube and transported to the laboratory within 6 hours. Samples were in 
culture within 8 hours of blood draw. The blood collections from HEU infants were performed 
from February 2010 to June 2012, and from the HU infants from June 2011 to August 2012.   
Whole blood was mixed in a 1:10 dilution with warm Roswell Park Memorial Institute (RPMI) 
1640 culture medium (Sigma Aldrich) without additives or antibiotics, and 1200ul/well was 
placed into a 24 well culture plate and incubated at 36
o
C with 5%CO2 without antibiotics. The 
Method Response type Pros Cons 
Oregon Green 
incorporation 
-(Soares et al., 2010) 







-Co-staining with other 
markers 
-Used with peripheral blood 
mono nuclear cells (PBMC) 
-Cannot use whole 
blood 
-Less robust (in 







-(Soares et al., 2010) 







-Co-staining with other 
markers 
-Used with PBMC 








-(Soares et al., 2010) 







-Co-staining with other 
markers 
-Used with PBMC 
 
 









-(Soares et al., 2010) 
T cell proliferation -Used with PBMC 
 
-Cannot use flow 
cytometry 






- (Soares et al., 2010) 
- (Soares et al., 2013) 
- (Hanekom et al., 2004) 
- (Remick, 1999) 







-Co-staining with other 
markers 
-Used with PBMC 
-Use whole blood 
-Robust  
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Mycobacterium bovis bacillus Calmette-Guérin 
(BCG) [Danish strain 1331; SSI], 0.16 IU Tetanus toxoid (TT) [TETAVAX, Aventis Pharma 
(Pty) Ltd], 0.16 IU Pertussis antigens (BP) [Difco
TM
 Bordetella Pertussis Antigen, BD] and a 
negative control (medium alone) (Figure 3.1a).  
After 24 hours of incubation 1ug/ml Staphylococcal enterotoxin b (SEB) was added to its 
required well and then cells were placed back at 36
o
C for a further 6 days(Soares et al., 2010). 
On the 6
th
 day, 0.001mg/ml of phorbol 12-myristate 13-acetate (PMA) and 0.005mg/ml 
Ionomycin was added which work synergistically to stimulate cells [PMA and Ionomycin 
stimulate intracellular production of cytokines by cells non-specifically and have been shown to 
work synergistically(Hanekom et al., 2004)(Soares et al., 2010)(Soares et al., 2013)], along with 
0.05mg/ml Brefeldin A which captures cytokines intracellularly, for the last 4 hours of 
incubation and the cells were harvested in 20mM EDTA.  
Negative control cells were stimulated with media alone on day 0 with Ionomycin and PMA on 
day 6. Positive controls cells were stimulated with SEB on day 1 and with Ionomycin and PMA 
on day 6.  After culture, red blood cells were lysed and white cells were stained with Pacific Blue 
Live/Dead stain [violet viability dye (VIVID)] before fixing with FACS Lysing Solution and 
cryopreserving in a 10% DMSO-containing solution for storage at -80
o
C until analysis. This 
assay was chosen due to the high yield of information obtainable from very small volumes of 
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Figure 3.1a: The whole blood assay procedure:  On day 0, whole blood diluted in RPMI was incubated with antigens 
(BCG, BP, TT and medium alone). SEB was added on day-1 (24 hours after incubation) to its required well, and the 
culture plate was placed back in the incubator till day 6. 
           
Figure 3.1b: The whole blood assay procedure day-6: PMA and Ionomycin and Brefeldin A were added to all wells 
for the last four hours of stimulation, after which the cells were harvested in 20mM EDTA, red blood cells (RBC) 
were lysed and white blood cells (WBC) stained with live/dead stain. Cells were further fixed in BD FACS Lysing 
solution, cryopreserved and stored at -80
0
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3.1.2 Proliferation measured by Ki67 incorporation and Intracellular cytokine 
staining assay (ICS) 
To answer the first, second and third specific objectives (section 1.7.1), fixed cryopreserved cells 
were thawed, permeabilized and stained for intracellular INF-γ, IL-2, IL-13 and IL-17 (ICS) and 
for cellular markers (CD3 and CD8) and for proliferation marker (Ki67) with optimised volumes 
of fluorescence-conjugated antibodies. Expression was measured by multiparameter flow 
cytometry (LSR Fortessa) using an eight colour panel (Table 3.3). 
Table 3.3: Eight colour flow cytometry panel: The eight colour flow cytometry panel employed with the various 
antibodies markers, fluorochrome, their suppliers, rational and their importance for inclusion in the panel.  
MARKER FLUOROCHROME CLONE SUPPLIER MARKER / FUNCTION 
Vivid Pacific Blue - Invitrogen Live/Dead / Dead cell marker 
CD3 APC-Cy7 UCHT1  Biolegend T-Lymphocytes / T lymphocyte marker 
CD8 PerCP-Cy5.5 SK1  BD  Biosciences Cytotoxic T-Lymphocytes / Kill infected cell 
Ki67 FITC B56  BD  Biosciences Proliferation / T cell proliferation marker 
IFN-γ Alexa Fluor 700 B27  Biolegend TH1 / Control of intracellular pathogens 
IL-2 APC 5344.111  BD  Biosciences TH1 / Growth and function of T-cells 
IL-13 PE JES10-5A2  BD  Biosciences TH2 / Directs antibody production by B cells 
IL-17  PE-Cy7 BL168 Biolegend TH17 / Recruits CD4 Th1 cells, Neutrophils 
and enhanced phagocytic killing 
 
3.2 Data analysis 
After flow cytometry acquisition, data was extracted for analysis. Below is a summary of the 
data analysis strategies.    
3.2.1 Flow cytometry data analysis 
After acquisition by flow cytometry, the files were first analyzed using FLOWJO v9.4.7 (Tree 
Star). After gating for singlets, live CD3+ cells, CD8+ cells and CD8- cells were gated (and 
regarded as CD4+ cells since PMA-Ionomycin causes CD4 degradation in T cells)(Rueggs et al., 
1992). CD4+Ki67+ and CD8+Ki67+ proliferating cells were then gated on CD8- (CD4+) and 
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(Th2) were then gated on within Ki67+ CD8- (CD4+) and CD8+ cells (Figure 3.2b). Boolean 
gating was used to quantify cells expressing a single or a combination of multiple cytokines. 
Appendix C below shows details on how the gates were determined, from the time gates for 
including consistent fluorescence over time and exclusion of doublets using forward scatter-area 
and forward scatter-height parameters in a singlets gate; to exclusion of dead cells [violet 
viability dye positive cells (VIVID+)] gating live CD3+ cells and gating CD8-(CD4+) and CD8+ 
T cells and finally Ki67 incorporated T cells. Appendix F below shows the median background 
response to evaluate the level of non-specific stimulation in the assay. 








                        Gating of Cytokine production from proliferating T cells (Next)        
Figure 3.2a: Gating of CD4+, CD8+ and Ki67+ proliferating T cells. (A) A representative flow cytometry 
plot of CD3+CD8- (CD4+) (left) and CD3+CD8+ (CD8+) (right) T cells and (B) CD4+Ki67+ (left) and 
CD8+Ki67+ (right) proliferating cells in response to Staphylococcal enterotoxin B [SEB] (Positive control). 
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Gating of Cytokine expressing cells from proliferating T cells   
     
(A)                                     CD4+Ki67+                                                  CD8+Ki67+ 
                                                    IFN-ϒ+  
 
(B) 
                                                                    
(C)                            
                                                              
    
(D) 
                                                      
 
Figure 3.2b: Gating of CD4+Ki67+ and CD8+Ki67+ cytokine producing T cells. A representative flow 
cytometry plot of CD4+Ki67+ (left) and CD8+Ki67+ (right) proliferating cells expressing intracellular 
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Staphylococcal enterotoxin B [SEB] – Positive control. The values represent the percentage of T cells that fall 
within the gates in this representative experiment. 
     
3.2.1.1 Standard rules for cut-offs and controls for the flow cytometry data 
Following analysis by FlowJo, the data was exported and organized for further analysis. In order 
to ensure no data bias and to perform background subtraction, the following rules were put in 
place:  
1.) Assay validity and positivity (before background subtraction) 
The frequency of proliferating cells in response to SEB had to be greater than the median plus 3 
times the Median Absolute Deviation (MAD) of the negative control, or the sample was 
excluded. MAD is a robust scale estimator about the median defined as the deviations of each 
sample negative control frequency from the negative control’s median, the MAD is the median 
of the absolute values of the deviation(Rouss et al., 1993). 
i.e. Frequency of CD4+ proliferating cells 
% Ki67+CD4+ [SEB] > % Ki67+CD4+ (Median + 3MAD) [Media] 
 
2.) Proportion of proliferating cells (Ki67+) 
The frequency of CD4+ and CD8+ T cells expressing Ki67 (i.e. CD4+Ki67+ and 
CD8+Ki67+ T cells) of the test antigens (BCG, BP, TT and SEB) minus background (% 
of Ki67+ CD4+ and CD8+ T cells in the media control) 
i.e. (i) [(BCG, BP and SEB induced %Ki67+CD4+ cells) – (Induced %Ki67+CD4+ 
cells in the media)]   
(ii) [(BCG, BP and SEB induced %Ki67+CD8+cells) – (Induced %Ki67+CD8+ cells 
in the media)] (Figure 3.3). 
3.)  Cut off for cytokine responses 
For single cytokine analyses (Chapter 5), data is reported as frequency of grandparent T 
cell population which was the frequency of total CD4+ and CD8+ T cells producing 
cytokines (i.e. the ratio of CD4+Ki67+ and CD8+Ki67+ T cells producing cytokines over  
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6) data is reported as the frequency of proliferating T cells producing cytokines i.e. the 
denominator is proliferating cells only.  
(a.) The test antigens (i.e. BCG, BP, TT and SEB) cytokine responses were only quantified 
if the event counts of proliferating T cells (i.e. CD4+Ki67+ T cells) were ≥ 20. 
(b.) Further, we performed background subtraction of the % of total CD4+ and CD8+ T cell 
cytokine production in the media from the % of total CD4+ and CD8+ T cell cytokine 
production due to the specific test antigens i.e. BCG, BP, TT and SEB (Figure 3.3). 
 
Figure 3.3: Schematic description of the frequencies of total CD4+ and CD8+ cells (grandparent population), 
antigen specific CD4+ and CD8+ proliferating cells (parent population) and antigen specific total CD4+ and CD8+ 
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3.3 Statistical considerations 
Different statistical packages were used to complete the data analysis after obtaining data from 
flow cytometry as listed in the table below (Table 3.4). 
Table 3.4: Statistical packages used for data analysis 
Parameters SOFTWARE PROGRAM ANALYSIS TYPE DATA TYPE 
1 FLOWJO v9.4.7 (for MAC, 
Stanford University, 1995-96; Tree 
Star, Inc. 1997-2012) 




2 Microsoft Excel 2007 To clean and organize data 
3 Pestle v1.7 (for MAC, Mario 
Roederer, National Institute of 
Allergy & Infectious Diseases, 2004-
2011) 
To perform background subtraction 
and organize data for SPICE 
4 SPICE v5.22 (for MAC, Mario 
Roederer-Joshua Nozzi, National 
Institute of Allergy & Infectious 
Diseases, 2004-2011) 
To analyze intracellular cytokine 
polyfunctionality between groups 
 
5 GraphPad Prism v5 (for Windows, 
GraphPad Software, San Diego 
California USA, 
www.graphpad.com”). 
To analyze differences in proliferation 
and absolute cytokine expression by 
cells between groups.  Graphics 
6 STATA v11 (for windows, StataCorp 
LP, College station, TX77845, USA). 








3.3.1 Statistical data analysis 
Data analysis was performed by applying the following statistical tests; 
 
Table 3.5: Statistical tests used to complete data analysis 
Statistical test Rationale Statistical 
package 
Data type 
Shapiro-Wilk test Confirm normality or non-normality of 
data distribution. If not normally 
distributed then data was log 
transformed for normal distribution 
STATA v11 -Cohort description 
- T cell Proliferation  
-T cell cytokine production 
-T cell polyfunctional 
cytokine responses 
Chi-square test Relationship between two categorical 
variables  
STATA v11 Cohort description 
(e.g. EBF vs. MF) 
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variables (one or more of the values in 




Compare continuous data between two 
categories that is not normally 
distributed. 
-STATA v11 
- GraphPad Prism 
v5 
- SPICE v5.22 
-T cell Proliferation  
-T cell cytokine production 
-T cell polyfunctional 
cytokine responses 




Compute comparisons between 
variables of interest at particular time 
points when adjusting for confounders 
- STATA v11 -T cell Proliferation  
-T cell cytokine production 





average models  
Compute comparisons between 
variables of interest through time from 
one time point to another 
- STATA v11 -T cell Proliferation  
-T cell cytokine production 





approach (based on 
the Bonferroni 
inequality P’), 
(Columb et al., 
2006). 
  
(i) the p-values for the each parameter 
measured for all conditions (m) were 
arranged in ascending order, (ii) 
starting with the smallest p-value, 
P’=(m)p, (iii) if significant, we 
proceeded to the next smallest p-value 
and calculated P’=(m-1)p, (iv) the step-
wise process was continued (…m-2,…) 
until P’>0.05, which we continued and 






3.3.1.1 Univariate analyses 
 
Data was first described through univariate analyses (primary variable being HIV-exposure) 
between HIV-exposed uninfected (HEU) and HIV-unexposed (HU) infants at two separate time 
points six and 14 weeks. Compa isons of categorical and continuous data between the two 
groups were performed using different statistical tests (Table 3.5).  
 
3.3.1.2 Multivariate analyses  
 
Multiple regression models were constructed by examining a priori variables based conceptual 
knowledge and not just on statically significance between the groups at baseline. HIV-exposure 
was the primary variable (Table 3.5). 
Generalized Estimation Equation (GEE) population average models were also constructed by 
examining variables of interest (Table 3.5) to evaluate the evolution of the T cell proliferation 
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weeks of life.  GEE could not be performed to BP and TT induced T cell proliferation and 
intracellular cytokine production since Bordetella pertussis and Tetanus toxoids vaccines were 
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4.1 Introduction  
We compared CD4+ and CD8+ T cell proliferative responses to vaccine antigens [Bacillus 
Calmette-Guérin (BCG), Bordetella pertussis (BP) and Tetanus toxoid (TT)] and to 
Staphylococcal enterotoxin B (SEB) and the consequences of HIV-1 exposure on the 
development of antigen specific cellular proliferative immune responses in early life between 
HEU versus HU infants. This was done by measuring the frequency of Ki-67-expressing CD4+ 
and CD8+ T-cells in 6 day whole blood assay cultures described in the methods (see section 
3.1.1) with samples collected at six and at 14 weeks of age from both HEU and HU infants.   
4.2 T-cell proliferative responses in HEU versus HU infants at 6 and at 14 
weeks of life 
The proliferative responses to BCG, BP, TT and SEB were compared between HEU versus HU 
infants.  
4.2.1 BCG-, BP- and TT-induced T-cell proliferative responses 
The p-values shown in Figure 4 are unadjusted. For BCG, there was no significant difference at 6 
weeks, however, at 14 weeks, after adjustment for multiple comparisons, the frequency of both 
CD4+ (median of HEU=21.9% versus HU 8.7% and p=0.2035) was not significant and CD8+ 
(median of HEU=16.0% versus HU 6.7% and p=0.009) remained significant. [Figure 
4.1(a)](Columb et al., 2006).  For BP and TT, no significant differences were observed between 
the two infant groups in the frequency of CD4+ and CD8+ proliferating T cells at 14 weeks of 
life [Figure 4.1 b and c). However, the number of samples with proliferating cells from which we 
could measure T cells proliferation in the HEU infants in response to TT was small. Appendix D 
below shows the number of HEU and HU infants whose CD4+ and CD8+ T cell proliferation 
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(a)      BCG-induced Ki67+ T cells 
                                                  Week 6                                                                                 Week 14 
                                               CD4+                 CD8+                                                        CD4+                   CD8+ 
              
Figure 4.1a: Frequency of proliferating T cells after Bacillus Calmette-Guérin (BCG) stimulation at 6 and 
14 weeks of life measured by flow cytometry. Frequency of CD4+ (in blue on the left side of each graph) and 
CD8+ (in black on the right side of each graph) proliferating T cells determined by flow cytometry in BCG-
stimulated whole blood of HIV-exposed uninfected infants (HEU: ovals) presented on the left of each side of the 
plot compared to HIV-unexposed infants (HU: triangles) presented on the right of each side of the plot at 6 and at 
14 weeks of life. Bars indicate medians; p<0.05 significant level (unadjusted) and statistical significance was 
obtained using Mann-Whitney U test.   
 
(b)                                BP-induced Ki67+ T cells     
Week 14 
                   CD4+                   CD8+ 
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(c)                                           TT-induced Ki67+ T cells   
                                                                                                     Week 14 
                                                                                               CD4+                    CD8+ 
                                            
Figure 4.1b-c: Frequency of proliferating T cells after Bordetella pertussis (BP) and Tetanus toxoid (TT) 
stimulation at 14 weeks of life measured by flow cytometry. Frequency of CD4+ (in blue on the left side of 
each graph) and CD8+ (in black on the right side of each graph) proliferating T cells determined by flow 
cytometry in (b) BP- and (c) TT-stimulated whole blood of HIV-exposed uninfected infants (HEU: ovals) 
presented on the left of each side of the plot compared to HIV-unexposed infants (HU: triangles) presented on 
the right of each side of the plot at 6 and at 14 weeks of life. Bars indicate medians; p<0.05 significant level 
(unadjusted) and statistical significance was obtained using Mann-Whitney U test.   
 
4.2.2 SEB-induced T-cell proliferative responses 
The p-values shown on the graph are the unadjusted ones. A significantly higher frequency of 
both the CD4+ (HEU median=42.9% versus HU median=12.6 and p=0.0264) and CD8+ (HEU 
median=62.3% versus HU median=20.2 and p=0.008) proliferating T cells after SEB stimulation 
was observed in the HEU versus their unexposed counterparts at 14 weeks after adjustment for 
















Chapter 4: T-cell proliferation in HEU vs. HU infants  47 
 
                                             SEB-induced Ki67+ T cells   
                                                   Week 6                                                                                 Week 14 
                                               CD4+                      CD8+                                                    CD4+                        CD8+ 
          
Figure 4.2: Frequency of proliferating T cell after Staphylococcal enterotoxin B (SEB) stimulation at 6 
and 14 weeks of life measured by flow cytometry. Frequency CD4+ (in blue on the left side of each graph) and 
CD8+ (in black on the right side of each graph) proliferating T cells determined by flow cytometry in SEB-
stimulated whole blood of HIV-exposed uninfected infants (HEU: ovals) presented on the left of each side of the 
plot compared to HIV-unexposed infants (HU: triangles) presented on the right of each side of the plot at 6 and at 
14 weeks of life. Bars indicate medians; p<0.05 significant level (unadjusted) and statistical significance was 
obtained using Mann-Whitney U test.   
 
 
4.3 Factors influencing antigen specific T cell proliferation  
Based on the observational nature of our cohort (see table 2.1), we took into consideration factors 
that could confound T cell proliferation between HEU versus HU infant groups in response to 
vaccine antigens (BCG, BP and TT) and SEB. 
4.3.1 Factors predicting BP- and TT- induced T cell proliferation at 14 weeks 
of life. 
A priori factors that could influence BP- and TT-  induced CD4+ and CD8+ T cell proliferation at 
14 weeks of age were assessed in regression analysis (Table 4.1), because following the Expanded 
Program on Immunization (EPI) schedule in South Africa, the first dose of these vaccines are 
administered only at 6 weeks of life. The results were presented and interpreted as etiological 
models assessing the strength of the association between HIV-exposure and T cell proliferation 
when taking other covariate into consideration.  
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The following a priori predictive variables were studied based on conceptual knowledge and not 
just on statistical association with the exposure (see table 2.1); (i) HIV-exposure, (ii) gestation age, 
(iii) birth weight, (iv) weight at 6 weeks, (v) exclusive breast feeding (EBF) at birth, (vi) EBF at 6 
weeks, (vii) age at 6 weeks, and (viii) age at 14 weeks. 
We went further to correct for these factors using linear regression models and a backward 
elimination process was used. Only the results of the exposure (HEU using HU as reference 
population) were reported, with note of which (if any) other covariates adjusted for created a 
difference in the exposure variable. We performed multivariate analysis with only three predictive 
variables where we had less than 5 children per response (Appendix D, Table D1), as a model with 
5 variables is unlikely to converge if there are less than 5 children in one of the two exposure 
groups (i.e. for TT at 14 weeks CD4+ and CD8+ T cell proliferation). 
In Model 1, HIV-exposure alone was not significantly associated with CD4+ or CD8+ T cell 
proliferation in response to either BP or TT at 14 weeks of life (Table 4.1). Model 2 demonstrate 
the predictive effect of gestational age on T cell proliferation. However, the modified coefficient 
(95% CI) of the HIV-exposure variable was still not significant and in subsequent models. Model 3 
accounts for the weight at birth and at 6 weeks. Additional potential confounders were introduced 
in Model 4 and 5. However, the number of samples for TT in the HEU infants was small. 
This result was opposite to that for BCG where proliferation was positively associated with HIV-
exposure alone unconfounded. This may be due to the type of antigen, suggesting that HIV-
exposed uninfected infant T cells were less able to proliferate in response to protein antigens.  
In these models, none of the other potential confounders were significant predictors of CD4+ or 
CD8+ T cell proliferation (Table 4.1), except for birth weight, when adjusting for HIV-exposure, 
gestational age, and weight at 6 weeks in Model 3. HIV exposure did not predicted T cell 
proliferation in responses to BP, but birth weight directly predicted CD4+Ki67+ responses to BP 
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Table 4.1: Factors predicting CD4+ and CD8+ antigen specific T cell proliferation at 14 weeks of life after 
stimulation with Bordetella pertussis (BP) and tetanus toxoid (TT) antigens, determined by linear regression 
models. Frequency of proliferating T cells (CD4+Ki67+ or CD8+Ki67+) after adjusting a priori confounders 
(variables) following BP and TT stimulation at 14 weeks of age. Condition = cond., Week = wk, exclusively breast 
feeding = EBF, coefficient = coef., and 95% confidence interval = 95% CI. Bold text represents variables that 
remain significant after multivariate adjustments for possible confounders. Not done = ND (where there was less 
than 5 children in one of the exposure groups).   
Cond. Variable 
Model 1 Coef. 
(95% CI)  
Model 2 Coef. 
(95% CI)  
Model 3 Coef. 
(95% CI) 
Model 4 Coef. 
(95% CI) 








Weight at 6 wk 
EBF at birth 
EBF at 6 wk 
Age at 6 wk  
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EBF at 6 wk 
Age at 6 wk  
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Weight at 6 wk 
EBF at birth 
EBF at 6 wk 
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4.3.2 Factors predicting BCG- and SEB- induced T cell proliferation 
longitudinally through time from 6 to 14 weeks of life 
Generalized Estimation Equation (GEE) population averaged model was used to predict the 
evolution of T cell immune responses longitudinally from 6 to 14 weeks of life in response to 
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potential confounder) that could influence BCG- and SEB- induced CD4+ and CD8+ T cell 
proliferation over time from 6 to 14 weeks of age (Table 4.2). The results were presented and 
interpreted as etiological models assessing the strength of the association between HIV-exposure 
and T cell proliferation when taking other covariate into consideration.  
The following a priori predictive variables were studied based on conceptual knowledge and not 
just on statistical association with the exposure (see table 2.1); (i) HIV-exposure, (ii) gestation age, 
(iii) birth weight, (iv) weight at 6 weeks, (v) exclusive breast feeding (EBF) at birth, (vi) EBF at 6 
weeks, (vii) age at 6 weeks, and (viii) age at 14 weeks. 
We went further to correct for these factors using GEE models and a backward elimination process 
was used. Only the results of the exposure (HEU using HU as reference population) were reported, 
with note of which (if any) other covariates adjusted for created a difference in the exposure 
variable. We performed multivariate analysis with only three predictive variables where we had 
less than 5 children per response (Appendix D, Table D1), as a model with 5 variables is unlikely 
to converge if there are less than 5 children in one of the two exposure groups (i.e. For TT at 14 
weeks CD4+ and CD8+ T cell proliferation). 
In Model 1, HIV-exposure alone unconfounded associated positively with CD4+ T cell 
proliferation longitudinally (Coefficient:11.83 and 95% CI: 1.64-22.02) (Table 4.2) and was the 
most important determinant of CD4+ T cell proliferation to BCG longitudinally when adjusting for 
other potential confounders including gestation age in Model 2 (Coefficient:12.47 and 95% CI: 
2.46-22.49), birth weight and weight at 6 weeks of age in Model 3 (Coefficient:11.49 and 95% CI: 
1.26-21.72) (Table 4.2). Model 4 and 5 include additional potential confounders EBF at birth and 
at 6 weeks, and the age at 6 and 14 weeks. However, the association of CD4+ T cell proliferation 
with HIV-exposure was no longer significant (Table 4.2).   
In Model 1, HIV-exposure alone unconfounded did not predict CD4+ T cell proliferation to SEB 
longitudinally (Table 4.2) and did not predict CD4+ T cell proliferation to SEB when adjusting for 
potential confounders including gestational age in Model 2, weight at birth and weight at 6 weeks 
of age in Model 3. Model 4 and 5 include additional potential confounders EBF at birth and at 6 
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In Model 1, HIV-exposure alone unconfounded did not predict CD8+ T cell proliferation to both 
BCG and SEB longitudinally (Table 4.2) and did not predict CD8+ T cell proliferation to both 
BCG and SEB when adjusting for potential confounders including gestational age in Model 2, 
weight at birth and weight at 6 weeks of age in Model 3. Model 4 and 5 include additional potential 
confounders EBF at birth and at 6 weeks, and the age at 6 and 14 weeks (Table 4.2). 
HIV-exposure may not be very important for SEB responses when adjusting for other confounders 
in Model 2 to 5. Also, the association between CD4+ T cell proliferations to BCG vaccination were 
evident as HIV-exposure positively predicted CD4+ T cell proliferation over time from 6 to 14 
weeks of age in response to BCG. The association between CD8+ T cell proliferation and HIV-
exposure was not evident, but gestation age in Model 2 positively predicted CD8+ proliferation 
(Table 4.2).   
Exposure in utero to HIV may stimulate T cells non-specifically to respond to other unrelated 
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Table 4.2: Generalized Estimation Equation (GEE) population averaged model predicting CD4+ and CD8+ 
antigen specific T cell proliferation after stimulation with Bacillus Calmette-Guérin (BCG) and 
Staphylococcal enterotoxin B (SEB) antigens longitudinally from 6 to 14 weeks of life. Frequency of 
proliferating T cells (CD4+Ki67+ or CD8+Ki67+) after adjusting a priori confounders (variables) following BCG 
and SEB stimulation at 6 and 14 weeks of age. Condition = cond., Week = wk, exclusively breast feeding = EBF, 
coefficient = coef., and 95% confidence interval = 95% CI. Red bold text represents the HIV-exposed variable that 
remains significant in a model and black bold text represents other variables that remain significant after 
multivariate adjustments for possible confounders.   
Cond. Variable 
Model 1 Coef. 
(95% CI)  
Model 2 Coef. 
(95% CI)  
Model 3 Coef. 
(95% CI) 
Model 4 Coef. 
(95% CI) 







Weight at 6 wk 
EBF at birth 
EBF at 6 wk 
Age at 6 wk  
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4.3 Discussion 
T cell proliferation is an important measure of vaccine immunogenicity and T cell function; and 
few studies have examined the effect of HIV-exposure on this parameter in infants (Mazzola et 
al., 2011). This study was partly designed to investigate the proliferative ability of CD4+ and 
CD8+ T lymphocytes in response to vaccine antigens [Bacillus Calmette-Guérin (BCG), 
Bordetella pertussis (BP) and Tetanus toxoids (TT)]; including Staphylococcal enterotoxin B 
(SEB) among infants exposed to HIV-1 in-utero compared with control infants not exposed to 
HIV.  
Ki-67 expression has been validated for measurement of in vitro proliferation after 6-day whole 
blood culture with antigens (Soares et al., 2010). The advantage of this marker is that it can be 
used with whole blood, whereas Oregon Green and CFSE cannot. It is robust compared to CFSE 
in terms of culture manipulability. Small blood volumes prohibited the use of the BrdU assay.  
In this chapter, we found that HIV-exposure enhance the proliferative response to BCG 
vaccination and to SEB. These findings were opposite to our original hypothesis, but consistent 
with reports of proliferative response in cord blood mononuclear cells (CBMC) from Brazilian 
HEU infants(Hygino et al., 2008). However, in contrast, Mazzola et al. found HEU infants had a 
reduced BCG-specific T cell proliferation(Mazzola et al., 2011).  
In support of our findings, Mazzola et al. have shown that T cell lymphoproliferation increased 
significantly with age in HEU infants in response to BCG reflecting the establishment of an 
immune response following BCG vaccination(Mazzola et al., 2011). SEB is used in many assays 
as a positive control, but biologically it can reveal important attributes of T cell functionality. 
SEB signals without the need for co-stimulatory molecules,  but only through certain and not all 
Vβ TCR such as V beta 8.1/8.2 T cells(Herz et al., 1999)(Renz et al., 1993). Hygino et al. also 
found an increased response to non-specific stimulation (anti-CD3 anti-CD28) in CBMC of HIV-
exposed infants born to HIV-infected mothers who had a high plasma viral load compared to 
CBMC of infants born to HIV-infected mothers who controlled their plasma viral load(Hygino et 
al., 2008). Significant increase in lymphoproliferation in response to non-specific stimulations 
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Further, looking at the GEE analyses, HIV-exposure was the most important predictor of CD4+ 
T cell proliferation longitudinally over time to 14 weeks of life in response to BCG after 
adjusting for other confounders. HIV-exposure did not predict CD8+ T cell proliferation 
longitudinally over time to 14 weeks of life in response to either BCG or SEB stimulation but 
gestation age was the most important determinate of CD8+ T cell proliferation longitudinally 
over time to 14 weeks in response to BCG, further suggesting that the immune response in these 
infants matures with age.    
The difference between the findings in this chapter and that of Mazzola et al. could be due to a 
wide number of factors, including the age range of their cohorts: the age of the cohort used for 
this thesis was from birth to 14 weeks and Hygino et al. used CBMC, whereas, Mazzola et al’s 
cohort was between 6.1 to 26.3 months infants, older than the infants in the other two. In 
addition, Mazzola et al. used the peripheral blood mononuclear cells (PBMCs) proliferation 
assay different from the whole blood assay (WBA) we used. The difference in assay type would 
require different storage methods that could affect the results.  Another likely factor influencing 
the difference in results is geographical location that would entail exposure to different 
environment clades, as they included HIV-exposed infants in Sao Paulo, Brazil while we had a 
South African cohort. It has been shown that immunological characteristics between African and 
European infants are different(Wilfing et al., 2001).   
This is also the first study comparing Bordetella pertussis and tetanus toxoid specific T cell 
proliferation in HEU versus HU infants. No significant difference in T cell proliferation was 
observed in response to these antigens between groups of infants at 14 weeks of life using 
regression analyses, although there were few numbers of TT samples. The infants showed a 
similar median CD4+ and CD8+ T cell proliferation between HEU versus HU groups at 14 
weeks of age.  
Therefore, the effect of HIV-exposure on vaccine immune responses may depend on the type of 
antigen. BCG is a live-attenuated organism that elicits strong cellular and antibody responses and 
often confers lifelong immunity with only one dose. Since it is a whole organism, it has many 
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toxin, has alum as an adjuvant, and needs to be processed in order to be presented by antigen 
presenting cells to T cells as well as BCG. Bordetella pertussis is a killed antigen that stimulates 
a weaker immune response than live vaccines, and requires booster doses to maintain a person’s 
immunity. This weak antigenicity may also determine how T cells respond in the assay. SEB is a 
superantigen that does not require antigen presentation and only results in certain CD4 or CD8 T 
cells to expand.   
It was hypothesised that HIV-exposure would decrease proliferative responses to vaccine 
antigens and SEB, but we found instead that T cell proliferation was significantly improved after 
BCG and SEB stimulation. This surprising finding may be due to in-utero perturbation of the T 
cell receptor (TCR) repertoire(Kou et al., 2000)(Halapi et al., 1999)(Alfani et al., 2000), as 
observed in individuals with HIV and after vaccination(Kou et al., 2000)(Soroosh et al., 2003); 
chronic immune activation and inflammation that might be encountered in the fetus of an HIV-
infected woman due to exposure to HIV antigens, and/or exposure to other maternal antigens 
such as opportunistic pathogens(Rich et al., 1997), or an immune dysfunction which could 
results in a lack of BCG containment in HEU infants that may allow more antigen exposure and 
at a later stage (e.g. 14 weeks of age) in life, and hyper-responsiveness to Superantigen, but 
would also cause weakened response to protein antigens.  
It may also be that BCG in vivo selects for specific Vβ TCR families, which expand and then 
respond better to SEB in the whole blood assay. V beta 8 gene family products have been found 
to respond to BCG(Wilson et al., 1993). Also, HIV-exposure, may delete (or expand) specific T 
cell clones (i.e. Vβ TCR) that are further expanded by BCG and then respond in vitro to SEB.  
The study as described has a few limitations; namely, the follow-up period was only 14 weeks, 
with time points at 6 and 14 weeks only. It would have been interesting to determine the peak 
response by the evolution of T cell proliferation through 8 and 10 weeks for the HEU infants in 
response to BCG for better kinetics. However, Kagina et al. demonstrated that 10 week old 
infants vaccinated with BCG at birth showed peak memory responses at 10 weeks following 
BCG vaccination (Kagina et al., 2009). Also, it was recently showed that CD4+ T cell responses 
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life(Soares et al., 2013). It has been shown that Bordetella pertussis (BP)(Esposito et al., 2001) 
and tetanus toxoid (TT) T cell responses after vaccination peak at 10 weeks after priming at 6 
weeks of age and did not wane after the last booster dose at 14 weeks of age at any time to 52 
weeks(Soares et al., 2013).  
Since this was an observational study, potential for bias could not be completely avoided by 
randomization. Hence the regression and GEE analyses were performed.  
These findings may have important implications for the optimal timing and vaccination strategies 
for HIV-exposed infants and may require careful immunological evaluation of future HIV and 
TB vaccines in this group. The clinical importance of these findings remains unknown. Further 
investigation is required as the observed T cell proliferative changes may result in alteration of 
HEU infant’s susceptibility to infections in addition to their already vulnerable state at later time 
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5.1 Introduction 
We aimed to compare the quality of CD4+ and CD8+ T cell intracellular cytokine production to 
vaccine antigens [Bacillus Calmette-Guérin (BCG), Bordetella pertussis (BP) and Tetanus 
toxoids (TT)] and in vitro to Staphylococcal enterotoxin B (SEB) in HIV-exposed uninfected 
(HEU) versus HIV-unexposed (HU) infants, to address the hypothesis that HEU infants produce 
lower quantity of cytokines. This was achieved by measuring the frequency of Th1 (IFN-γ and 
IL-2), Th2 (IL-13) and Th17 (IL-17) cytokines expression by proliferating antigen-specific T 
cells in HEU versus HU infants at 6 and at 14 weeks of life.  
Neonates have limited capacity to produce IFN-γ and cell-mediated immune responses involving 
cytotoxicity against intracellular pathogens(Siegrist, 2007)(Ota et al., 2012). IL-2 stimulates 
resting T cells and supports long term growth, activation, and proliferation of T cells (Smith, 
1988).  IL-2 is also a potent modulator of T and NK cell function, and it is the most extensively 
investigated cytokine to date. Vaccination at birth with BCG has been shown to significantly 
enhance Th1 responses to mycobacterial antigens(Burl et al., 2012). IFN-γ production increases 
with age in infants(Mazzola et al., 2011). 
IL-13 possesses a number of anti-inflammatory and immunomodulatory activities. African 
neonates mount significantly higher IL-13 responses to mitogens compared to Europeans, 
possibly reflecting continuous stimulation of antigens that preferentially drive its 
responses(Wilfing et al., 2001). 
Th17 cells may be important in vaccine-induced memory immune responses to bacterial 
antigens. IL-17 has been shown to populate the lungs, the primary site of Mycobacteria 
tuberculosis infections, and in turn recruit IFN-γ producing antigen-specific T cells persistent in 
the central lymphoid organs(Lin et al., 2011). 
In this chapter, the frequency of cytokine expression by proliferating antigen-specific T cells was 
reported as a frequency of total CD4+ and CD8+ lymphocytes. The intracellular cytokine 
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It is generally known that antigen-induced T cell proliferation measures the expansion of 
antigen-specific T cells, this further provides for the measurement of cytokine production by the 
proliferating cells(Anthony et al., 2012).  In general, measuring cytokine production by 
proliferating T cells permits a distinction between naïve and memory T cells. Memory cells are 
capable of the production of cytokines within a short while, for instance within 12 hours after 
antigen challenge, while naïve T cells must first undergo proliferation and differentiation before 
they can express cytokines(Mempel et al., 2004)(MATESIC et al., 1998)(Sallusto et al., 2004).  
 
The data in this chapter for the cytokine producing cells is presented in the following order; 
BCG, BP, TT and SEB and then IFN-γ, IL-2, IL-17 and IL-13 cytokine producing T cells. A 
summary presenting the data on the graphs is show on Table 5.1 followed by univariate and 
multivariate analysis adjusting for potential confounders.  Statistical analysis was performed 
using GraphPad prism v5 and linear regression analyses, with alpha=0.05 and statistical 
significance was tested using Mann-Whitney U test (see table 3.3).  
 
5.2 Cytokine production by antigen specific T cells at 6 and 14 weeks of life 
The p-values shown on the graph are the unadjusted ones. At 6 weeks of age, significant 
differences in the frequencies of CD4+ cytokine producing cells between the two groups of 
infants in response to TT, BP, and SEB were not evident. After adjustment for multiple 
comparisons by using the Holm step-down approach, there was no significant in the frequency of 
CD8+ T cells producing IL-13 in HEU compared to HU infants in response to BCG (p=0.1270) 
at 6 weeks of age. Please see Table 5.1 ahead for a summary of the results(Columb, 2006).   
At 14 weeks, after adjustment for multiple comparisons, there were no significant differences in 
the frequency of IL-13 (p=0.1830) and IL-17 (p=0.0615) production by CD4+ T cells in 
response to BCG between HEU versus HU infants. After adjustment for multiple comparisons, 
there was no significant differences in the frequency of IL-17 (p=0.1432) production by CD4+ T 
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Also at 14 weeks, after adjustment for multiple comparisons HEU infants’ CD8+ T cells 
produced a significantly lower frequency of IL-13 (p=0.0485) and IL-17 (p=0.0375) compared to 
HU infants in response to BCG (Table 5.1). Appendix D below shows the number of HEU and 
HU infants for whom measurement of CD4+ and CD8+ T cell cytokine production responses to 
the different antigens was performed.  
 
 
5.2.1 BCG-induced cytokine producing T-cell responses in HEU versus HU 
infants at 6 and 14 weeks of life 
5.2.1.1 IFN-γ and IL-2 cytokine producing cells induced by BCG in HEU 
versus HU infants at 6 and 14 weeks of life 
Figure 5.1 shows that no significant differences in the frequency of IFN-γ and IL-2 production 
by antigen-specific CD4+ and CD8+ T cells out of total CD4+ and CD8+ T cells in response to 
BCG observed between HEU versus HU infants at 6 and at 14 weeks of age.  
 
                   (a)             BCG-induced IFN-γ production by T cells 
                                  Week 6                                           Week 14 
                                          CD4+               CD8+                                                  CD4+                CD8+ 
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(b)               BCG-induced IL-2 production by T cells 
                           
 
Figure 5.1: The frequency of T cells producing IFN-γ and IL-2 after BCG stimulation for 6 days in whole 
blood assay at 6 and 14 weeks of life. Frequency of antigen-specific (a) IFN-γ and (b) IL-2 producing T cells out of 
total CD4+ (in blue on the left side of each graph) and CD8+ (in black on the right side of each graph) T cells,  
determined by flow cytometry of BCG-stimulated whole blood of HIV-exposed uninfected infants (HEU: ovals) 
presented on the left of each side of the plot compared to HIV-unexposed infants (HU: triangles) presented on the 
right of each side of the plot at 6 and at 14 weeks of life. Frequencies reported are the frequency of proliferating 
cytokine producing cells out of total CD4+ or CD8+ T cells. Bars indicate medians; alpha=0.05 (unadjusted); 






5.2.1.2 IL-17 cytokine producing cells induced by BCG in HEU versus HU 
infants at 6 and 14 weeks of life 
Figure 5.2 shows that at 14 weeks, in response to BCG, there was a significantly higher 
frequency of IL-17 (p=0.0123) production by CD4+ T cells in HEU infants and a significantly 
lower frequency of IL-17 (p=0.0075) production by CD8+ T cells in HEU compared to HU 
infants, but no significant differences were observed at 6 weeks of life.  
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BCG-induced IL-17 production by T cells 
                                  Week 6                                           Week 14 
                                          CD4+               CD8+                                                  CD4+                CD8+ 
                                
Figure 5.2: The frequency of IL-17 producing T cells at 14 weeks after BCG stimulation for 6 days in whole 
blood but not at 6 weeks of life. Frequency of antigen specific IL-17 producing T cells out of total CD4+ (in blue 
on the left side of each graph) and CD8+ (in black on the right side of each graph) T cells,  determined by flow 
cytometry of BCG-stimulated whole blood of HIV-exposed uninfected infants (HEU: ovals) presented on the left of 
each side of the plot compared to HIV-unexposed infants (HU: triangles) presented on the right of each side of the 
plot at 6 and at 14 weeks of life. Frequencies reported are the frequency of proliferating cytokine producing cells out 
of total CD4+ or CD8+ T cells. Bars indicate medians; alpha=0.05 (unadjusted); statistical significance was tested 







5.2.1.3 IL-13 cytokine producing cells induced by BCG in HEU versus HU 
infants at 6 and 14 weeks of life 
HIV-exposure affected the IL-13 response to BCG markedly. At 6 weeks of age, HEU infants 
had a significantly lower IL-13 (p=0.0254) production by CD8+ T cells compared to HU infants 
in response to BCG; and at 14 weeks, HEU infants had a significantly higher frequency of IL-13 
(p=0.0366) production by CD4+ T cells in response to BCG and a significantly lower IL-13 
(p=0.0097) production by CD8+ T cells in response to BCG (Figure 5.3).  
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                                 BCG-induced IL-13 production by T cells 
                                  Week 6                                           Week 14 
                                          CD4+               CD8+                                                  CD4+                CD8+ 
                           
Figure 5.3: The frequency of IL-13 producing T cells after BCG stimulation for 6 days in whole blood assay 
at 6 and at 14 weeks of life. Frequency of antigen specific IL-13 producing T cells out of total CD4+ (in blue on the 
left side of each graph) and CD8+ (in black on the right side of each graph) T cells,  determined by flow cytometry 
of BCG-stimulated whole blood of HIV-exposed uninfected infants (HEU: ovals) presented on the left of each side 
of the plot compared to HIV-unexposed infants (HU: triangles) presented on the right of each side of the plot at 6 
and at 14 weeks of life. Frequencies reported are the frequency of proliferating cytokine producing cells out of total 
CD4+ or CD8+ T cells. Bars indicate medians; alpha=0.05 (unadjusted); statistical significance was tested using 
Mann-Whitney U test.   
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5.2.2 BP-induced cytokine producing T-cell responses in HEU versus HU 
infants at 14 weeks of life 
5.2.2.1 IFN-γ and IL-2 cytokine producing cells induced by BP in HEU versus 
HU infants at 14 weeks of life  
We assessed BP- induced cytokine production by CD4+ and CD8+ T cells at 14 weeks of age 
only, because the first dose of these vaccines is administered at 6 weeks of life. Figure 5.4 shows 
that no significant differences in the frequency of IFN-γ and IL-2 production by CD4+ and 
CD8+ T cells in response to BP were observed between HEU versus HU infants at 14 weeks of 
age. However, the number of samples with proliferating cells from which we could measure 
IFN-γ and IL-2 production by T cells in response to BP was small.  
                (a)             BP-induced IFN-γ production by T cells 
Week 14 
CD4+                CD8+ 
                                  
                     (b)       BP-induced IL-2 production by T cells 
                                   
Figure 5.4: The frequency of T cells producing IFN-γ and IL-2 after BP stimulation for 6 days in whole blood 
assay at 14 weeks of life. Frequency of antigen-specific (a) IFN-γ and (b) IL-2 producing T cells out of total CD4+ 
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flow cytometry of BP-stimulated whole blood of HIV-exposed uninfected infants (HEU: ovals) presented on the left 
of each side of the plot compared to HIV-unexposed infants (HU: triangles) presented on the right of each side of 
the plot at 14 weeks of life. Frequencies reported are the frequency of proliferating cytokine producing cells out of 
total CD4+ or CD8+ T cells. Bars indicate medians; alpha=0.05 (unadjusted); statistical significance was tested 
using Mann-Whitney U test.   
 
 
5.2.2.2 IL-17 producing cells induced by BP in HEU versus HU infants at 14 
weeks of life   
Figure 5.5 shows that no significant differences in the frequency of IL-17 production by CD4+ 
and CD8+ T cells in response to BP were observed between HEU versus HU infants at 14 weeks 
of age, but the number of samples with proliferating cells from which we could measure IL-17 
production by T cells in response to BP was small.  
                                    BP-induced IL-17 production by T cells 
Week 14 
CD4+                CD8+ 
                                 
Figure 5.5: The frequency of T cells producing IL-17 after BP stimulation for 6 days in whole blood assay at 
14 weeks of life. Frequency of antigen specific IL-17 producing T cells out of total CD4+ (in blue on the left side of 
each graph) and CD8+ (in black on the right side of each graph) T cells, determined by flow cytometry of BP-
stimulated whole blood of HIV-exposed uninfected infants (HEU: ovals) presented on the left of each side of the 
plot compared to HIV-unexposed infants (HU: triangles) presented on the right of each side of the plot at 14 weeks 
of life. Frequencies reported are the frequency of proliferating cytokine producing cells out of total CD4+ or CD8+ 
T cells. Bars indicate medians; alpha=0.05 (unadjusted); statistical significance was tested using Mann-Whitney U 
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5.2.2.3 IL-13 cytokine producing cells induced by BP in HEU versus HU 
infants at 14 weeks of life 
Figure 5.6 shows that no significant differences in the frequency of IL-13 production by CD4+ 
and CD8+ T cells in response to BP was observed between HEU versus HU infants at 14 weeks 
of age, but the number of samples with proliferating cells from which we could measure IL-13 
production by T cells in response to BP in the HEU infants was small.  
                                  BP-induced IL-13 production by T cells 
Week 14 
  CD4+                CD8+ 
                                
Figure 5.6: The frequency of T cells producing IL-13 after BP stimulation for 6 days in whole blood assay at 
14 weeks of life. Frequency of antigen specific IL-13 producing T cells out of total CD4+ (in blue on the left side of 
each graph) and CD8+ (in black on the right side of each graph) T cells,  determined by flow cytometry of BP-
stimulated whole blood of HIV-exposed uninfected infants (HEU: ovals) presented on the left of each side of the 
plot compared to HIV-unexposed infants (HU: triangles) presented on the right of each side of the plot at 14 weeks 
of life. Frequencies reported are the frequency of proliferating cytokine producing cells out of total CD4+ or CD8+ 
T cells. Bars indicate medians; alpha=0.05 (unadjusted); statistical significance was tested using Mann-Whitney U 
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5.2.3 TT-induced cytokine producing T-cell responses in HEU versus HU 
infants at 6 and 14 weeks of life 
5.2.3.1 IFN-γ and IL-2 cytokine producing cells induced by TT in HEU versus 
HU infants at 14 weeks of life  
Figure 5.7 shows that no significant differences in the frequency of IFN-γ and IL-2 production 
by CD4+ and CD8+ T cells in response to TT were observed between HEU versus HU infants at 
14 weeks of age, but the number of samples with proliferating cells from which we could 
measure IFN-γ and IL-2 production by T cells in response to TT was small.  
                (a)             TT-induced IFN-γ production by T cells 
     Week 14 
CD4+                CD8+ 
                                 
                     (b)       TT-induced IL-2 production by T cells 
                                
Figure 5.7: The frequency of T cells producing IFN-γ and IL-2 at 14 weeks of life after TT stimulation for 6 
days in whole blood assay measured by flow cytometry. Frequency of antigen specific (a) IFN-γ and (b) IL-2 
producing T cells out of total CD4+ (in blue on the left side of each graph) and CD8+ (in black on the right side of 
each graph) T cells,  determined by flow cytometry of TT-stimulated whole blood of HIV-exposed uninfected 
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triangles) presented on the right of each side of the plot at 14 weeks of life. Frequencies reported are the frequency 
of proliferating cytokine producing cells out of total CD4+ or CD8+ T cells. Bars indicate medians; alpha=0.05 
(unadjusted); statistical significance was tested using Mann-Whitney U test.   
 
5.2.3.2 IL-17 cytokine producing cells induced by TT in HEU versus HU 
infants at 14 weeks of life  
Figure 5.8 shows that at 14 weeks, after TT stimulation a significantly lower frequency of IL-17 
(p=0.0358) production by CD4+ T cells was observed in HEU compared to HU infants, despite 
that the number of samples with proliferating cells from which we could measure IL-17 
production in response to TT was small.  
                                    TT-induced IL-17 production by T cells 
Week 14 
      CD4+                CD8+ 
                               
Figure 5.8: The frequency of IL-17 producing T cells at 14 weeks of life after TT stimulation for 6 days in 
whole blood assay measured by flow cytometry. Frequency of antigen specific IL-17 producing T cells out of 
total CD4+ (in blue on the left side of each graph) and CD8+ (in black on the right side of each graph) T cells,  
determined by flow cytometry of TT-stimulated whole blood of HIV-exposed uninfected infants (HEU: ovals) 
presented on the left of each side of the plot compared to HIV-unexposed infants (HU: triangles) presented on the 
right of each side of the plot at 14 weeks of life. Frequencies reported are the frequency of proliferating cytokine 
producing cells out of total CD4+ or CD8+ T cells. Bars indicate medians; alpha=0.05 (unadjusted); statistical 
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5.2.3.3 IL-13 cytokine producing cells induced by TT in HEU versus HU 
infants at 14 weeks of life  
Figure 5.9 shows that no significant differences in the frequency of IL-13 production by CD4+ 
and CD8+ T cells in response to TT were observed between HEU versus HU infants at 6 and at 
14 weeks of age, but the number of samples with proliferating cells from which we could 
measure IL-13 production in response to TT was small. 
                                    TT-induced IL-13 production by T cells 
                                                           Week 14 
                                                                         CD4+                CD8+ 
                        
 
Figure 5.9: The frequency of T cells producing IL-13 at 14 weeks of life after TT stimulation for 6 days in 
whole blood assay measured by flow cytometr . Frequency of antigen specific IL-13 producing T cells out of 
total CD4+ (in blue on the left side of each graph) and CD8+ (in black on the right side of each graph) T cells,  
determined by flow cytometry of TT-stimulated whole blood of HIV-exposed uninfected infants (HEU: ovals) 
presented on the left of each side of the plot compared to HIV-unexposed infants (HU: triangles) presented on the 
right of each side of the plot at 14 weeks of life. Frequencies reported are the frequency of proliferating cytokine 
producing cells out of total CD4+ or CD8+ T cells. Bars indicate medians; alpha=0.05 (unadjusted); statistical 
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5.2.4 SEB-induced cytokine producing T-cell responses in HEU versus HU 
infants at 6 and 14 weeks of life 
5.2.4.1 IFN-γ and IL-2 cytokine producing cells induced by SEB in HEU 
versus HU infants at 6 and 14 weeks of life  
Figure 5.10 shows that no significant differences in the frequency of IFN-γ and IL-2 production 
by CD4+ and CD8+ T cells in response to SEB were observed between HEU versus HU infants 
at 6 and at 14 weeks of age. 
                
(a)             SEB-induced IFN-γ production by T cells 
                                  Week 6                                             Week 14 
                                          CD4+               CD8+                                                  CD4+                CD8+ 
                           
                      
                  (b)          SEB-induced IL-2 production by T cells 
                                       
 
Figure 5.10: The frequency of T cells producing IFN-γ and IL-2 at 6 and 14 weeks of life after SEB 
stimulation for 6 days in whole blood assay measured by flow cytometry. Frequency of antigen specific (a) IFN-
γ and (b) IL-2 producing T cells out of total CD4+ (in blue on the left side of each graph) and CD8+ (in black on the 
right side of each graph) T cells,  determined by flow cytometry of SEB-stimulated whole blood of HIV-exposed 
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uninfected infants (HEU: ovals) presented on the left of each side of the plot compared to HIV-unexposed infants 
(HU: triangles) presented on the right of each side of the plot at 6 and at 14 weeks of life. Frequencies reported are 
the frequency of proliferating cytokine producing cells out of total cd4 or CD8 T cells. Bars indicate medians; 
alpha=0.05 (unadjusted); statistical significance was tested using Mann-Whitney U test. 
   
5.2.4.2 IL-17 cytokine producing cells induced by SEB in HEU versus HU 
infants at 6 and 14 weeks of life 
Figure 5.11 shows that no significant differences in the frequency of IL-17 production by total 
CD4+ and CD8+ T cells in response to SEB were observed between HEU versus HU infants at 6 
and at 14 weeks of age. 
                                  
SEB-induced IL-17 production by T cells 
                                  Week 6                                           Week 14 
                                          CD4+               CD8+                                                  CD4+                CD8+ 
                                            
Figure 5.11: The frequency of T cells producing IL-17 at 6 and 14 weeks of life after SEB stimulation for 6 
days in whole blood assay measured by flow cytometry. Frequency of antigen specific IL-17 producing T cells 
out of total CD4+ (in blue on the left side of each graph) and CD8+ (in black on the right side of each graph) T cells,  
determined by flow cytometry of SEB-stimulated whole blood of HIV-exposed uninfected infants (HEU: ovals) 
presented on the left of each side of the plot compared to HIV-unexposed infants (HU: triangles) presented on the 
right of each side of the plot at 6 and at 14 weeks of life. Frequencies reported are the frequency of proliferating 
cytokine producing cells out of total CD4+ or CD8+ T cells. Bars indicate medians; alpha=0.05 (unadjusted); 
statistical significance was tested using Mann-Whitney U test.   
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5.2.4.3 IL-13 cytokine producing cells induced by SEB in HEU versus HU 
infants at 6 and 14 weeks of life  
Figure 5.12 shows that no significant differences in the frequency of IL-13 production by CD4+ 
and CD8+ T cells in response to SEB were observed between HEU versus HU infants at 6 and at 
14 weeks of age. 
                                    
SEB-induced IL-13 production by T cells 
                                  Week 6                                           Week 14 
                                          CD4+               CD8+                                                  CD4+                CD8+ 
                                 
Figure 5.12: The frequency of T cells producing IL-13 at 6 and 14 weeks of life after SEB stimulation for 6 
days in whole blood assay measured by flow cytometry. Frequency of antigen specific IL-13 producing T cells 
out of total CD4+ (in blue on the left side of each graph) and CD8+ (in black on the right side of each graph) T cells,  
determined by flow cytometry of SEB-stimulated whole blood of HIV-exposed uninfected infants (HEU: ovals) 
presented on the left of each side of the plot compared to HIV-unexposed infants (HU: triangles) presented on the 
right of each side of the plot at 6 and at 14 weeks of life. Frequencies reported are the frequency of proliferating 
cytokine producing cells out of total CD4+ or CD8+ T cells. Bars indicate medians; alpha=0.05 (unadjusted); 
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5.2.5 Summary table of all the cytokines producing T cells measured 
Table 5.1 below presents the summary of results as shown on the graphs on Figures 5.1 – 5.12 
above. After adjusting p-values for multiple comparisons only the frequencies of IL-13 and IL-17 
cytokine production by CD8+ T cells remain significant. 
Table 5.1: The frequency of CD4+ and CD8+ cytokine producing T cells, in HEU versus HU infants. Antigen 
specific [Bacillus Calmette-Guérin (BCG), Bordetella pertussis (BP), Tetanus toxoid (TT) and Staphylococcal 
enterotoxin B (SEB)] CD4+ and CD8+ cytokine producing T cells at 6 and 14 weeks of life. Read outs for each 
condition, time point (TP), and cytokine include the median frequency of CD4+ and CD8+ cytokine producing cells 
and the significant difference indicated by the p-value unadjusted (and adjusted for multiple comparisons in 
parentheses if significant before adjusted) between HEU vs. HU infants. Adjustment for multiple comparisons was 
done using the Holm step-down approach(Columb et al.,, 2006) (see table 3.5). Cells indicated N/A are not 
applicable, since BP* and TT* are administered to infants in DTaP vaccine for the first time at 6 weeks only. Red 
highlights; represent p-values (and adjusted p-values) that remain significant after adjustment for multiple 




Median frequency (% of total CD4+ or CD8+ cells) of cytokine producing cells 
CD4+ CD8+ 
HEU HU p-value (adjusted) HEU HU p-value (adjusted) 
BCG 
(Week 6) 
IFN-ϒ  6.3 5.7 0.7000 6.7 7.4 0.7771 
IL-2 1.6 2.5 0.6755 1.6 2.4 0.4006 
IL-13 1.6 2.2 0.3044 0.09 0.4 0.0254 (0.1270) 
IL-17 1.5 1.3 0.5407 0.5 0.8 0.0774 
BCG 
(Week 14) 
IFN-ϒ  2.4 1.8 0.4982 1.8 1.4 0.3085 
IL-2 0.9 0.4 0.1071 0.3 0.4 0.8517 
IL-13 1.2 0.6 0.0366 (0.1830) 0.05 1.0 0.0097 (0.0485) 
IL-17 1.8 0.6 0.0123 (0.0615) 0.2 1.0 0.0075 (0.0375) 
BP* 
(Week 14) 
IFN-ϒ  0.0 1.6 0.1757 0.0 0.2 0.5500 
IL-2 1.3 1.9 0.9250 0.0 0.4 0.1424 
IL-13 9.7 5.8 0.7758 0.0 0.6 0.2704 




IFN-ϒ  0.4 1.1 0.4236 0.08 0.3 0.5519 
IL-2 0.8 1.0 0.5676 0.2 0.8 0.7143 
IL-13 0.4 1.8 0.2500 0.1 1.6 0.0667 




IFN-ϒ  7.42 4.0 0.2094 3.7 1.8 0.2052 
IL-2 1.9 1.8 0.8791 5.6 1.1 0.0590 
IL-13 0.1 0.7 0.6124 0.2 0.4 0.7727 




IFN-ϒ  3.2 1.4 0.1135 1.6 0.7 0.0693 
IL-2 0.9 0.6 0.4379 0.7 0.4 0.1008 
IL-13 0.7 0.5 0.5567 0.2 0.3 0.1769 
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5.3 Factors influencing antigen specific cytokine production by T cells at 6 and 
14 weeks of life 
Due to the observational nature of this cohort, there were a priori factors (every potential 
confounder) other than HIV-exposure (see table 2.1) which could also affect CD4+ and CD8+ T 
cell responses. We therefore aimed to adjust for these factors in regression and Generalized 
Estimation Equation (GEE) population averaged models. 
 
5.3.1 Factors predicting BP- and TT- induced cytokine production by T cells 
at 14 weeks of life 
We aimed to predict cytokine production by T cells, correcting for a priori factors (every potential 
confounder) that could influence BP- and TT- induced CD4+ and CD8+ T cell cytokine 
production at 14 weeks of age. However, the production of none of the cytokines assessed (IFN-γ, 
IL-2, IL-13 and IL-17) was significantly different between the two groups of infant in the 
bivariate analysis after stimulation with BP and TT; hence regression analysis were not 
performed.  
 
5.3.2 Factors predicting BCG- and SEB- induced cytokine production by T 
cells longitudinally through time from 6 to 14 weeks of life 
We aimed to use Generalized Estimation Equation (GEE) population averaged models to predict 
the evolution of T cell cytokine responses longitudinally from 6 to 14 weeks of life in response 
to BCG vaccination and SEB stimulation over time; and to adjust for a priori factors (every 
potential confounder) that could influence BCG- and SEB- induced CD4+ and CD8+ T cell 
cytokine production over time from 6 to 14 weeks of age (Table 5.2).  GEE analysis was only 
performed for significantly different cytokine responses observed in the bivariate analysis (i.e. 
IL-13 and IL-17 production by CD4+ and CD8+ T cells found following BCG stimulation at 
week 14). The results were presented and interpreted as etiological models assessing the strength 
of the association between HIV-exposure and T cell proliferation when taking other covariate 
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The following a priori predictive variables were studied based on conceptual knowledge and not 
just on statistical association with the exposure (see table 2.1); (i) HIV-exposure, (ii) gestation age, 
(iii) birth weight, (iv) weight at 6 weeks, (v) exclusive breast feeding (EBF) at birth, (vi) EBF at 6 
weeks, (vii) age at 6 weeks, and (viii) age at 14 weeks. 
We went further to correct for these factors using GEE models and a backward elimination process 
was used. Only the results of the exposure (HEU using HU as reference population) were reported, 
with note of which (if any) other covariates adjusted for created a difference in the exposure 
variable. We performed multivariate analysis with only three predictive variables where we had 
less than 5 children per response in any of the group (Appendix D, Table D1), as a model with 5 
variables is unlikely to converge if there are less than 5 children in one of the two exposure groups 
(i.e. For TT at 14 weeks CD4 and CD8 proliferation). 
In Model 1, HIV-exposure alone unconfounded did not associate with IL-13+ production by either 
CD4+ or CD8+ and with IL-17+ production by CD8+ T cells; but predicted IL-17+ production by 
CD8+ T cells (Coefficient:-11.36 and 95% CI:-18.7 - -3.9)  negatively following BCG stimulation 
longitudinally (Table 5.2). After adjusting for other confounders, Model 2 gestation age, HIV-
exposure did not predict production of any of the cytokines, except negative association with IL-
17+ production by CD8+ T cells that became (Coefficient:-10.98 and 95% CI:-18.3 - -3.6) in 
response to BCG longitudinally through time to 14 weeks of age (Table 5.2).  In Model 3 and 4 
additional potential confounders such as weight at birth and at 6 weeks and exclusively breast 
feeding at birth and 6 weeks respectively. HIV-exposure did not still predict cytokine production 
except for IL-17+ by CD8+ T cells that associated negatively that became (Coefficient:-10.56 and 
95% CI:-18.1 - -3.1) in Model 3, and (Coefficient:-11.32 and 95% CI:-21.9 - -0.7) in Model 4 
(Table 5.2).  In Model 5, the age at 6 and 14 weeks was added, HIV-exposure did not still associate 
to the production of any of the cytokines and the association observed with IL-17+ by CD8+ T 
cells disappeared (Table 5.2).  
This analysis showed that HIV exposure was an important predictor of IL-17+ production by 
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Table 5.2: Generalized Estimation Equation (GEE) population averaged model predicting total CD4+ and 
CD8+ antigen specific cytokine producing T cells after 6 day whole blood assay stimulation with Bacillus 
Calmette-Guérin (BCG) over time, from 6 to 14 weeks of life. Frequency of CD4+ and CD8+ cytokine producing 
T cells after adjusting a priori confounders (variables) following BCG and SEB stimulation at 6 and 14 weeks of 
age.  Condition = cond., Week = wk, exclusively breast feeding = EBF, coefficient = coef., and 95% confidence 
interval = 95% CI. Red bold text represents the HIV-exposed variable that remains significant in a model and black 
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5.4 Discussion 
Generating vaccine-mediated protection in infants is a complex challenge(Siegrist, 2007). There 
is limited understanding of the cellular immune responses currently available vaccines elicit in 
infants and less known about HIV-exposed uninfected (HEU) infants’ responses. In Chapter 4, we 
showed that HIV-1 influences both BCG- and SEB- CD4+ and CD8+ T cell proliferation at 14 
weeks significantly higher in the HEU versus HU infants but not at 6 weeks, and has no influence 
on BP-, and TT-induced CD4+ and CD8+ T cell proliferation. However, after adjusting for other 
confounders in a multivariate regression analysis in a model including the age BCG was 
administered in days, birth weight, weight at 6 weeks and the age at 14 week visit, HIV-exposure 
was the most important determinate of CD8+ T cell proliferation in response to TT at 14 weeks of 
life. 
Cytokines are also important factors to measure in immunogenicity, as cytokines are the 
molecules that regulate the function of immune cells and little is known about the effect of HIV-
exposure on this parameter. In this chapter the hypothesis was that HEU infants would have lower 
cytokine producing T cells to vaccine antigens and in vitro to SEB compared to HU infants.  
Some studies have documented findings when measuring cellular immunogenicity of 
mycobacterial and other antigens in this vulnerable group of infants(Mansoor et al., 2010)(Van 
Rie et al., 2006)(Mazzola et al., 2011)(Borges-almeida et al., 2011)(Hygino et al., 2008). The 
aims of this chapter were to compare the quality and magnitude of CD4+ and CD8+ T cell 
intracellular cytokine production to vaccine antigens [Bacillus Calmette-Guérin (BCG), 
Bordetella pertussis (BP) and Tetanus toxoids (TT)], and a mitogen Staphylococcal enterotoxin B 
(SEB) in HEU versus HU infants. 
It is important to note that cytokine expression was quantified in the actively proliferating, Ki67+ 
cells. The whole blood assay (WBA) was the method applied to quantify CD4+Ki67+ and 
CD8+Ki67+ T cells that produced intracellular cytokines (i.e. IFN-γ, IL-2, IL-13 and IL-17) as 
described in the methods (See sections 3.1.1 and 3.1.2). The ability to measure cytokine 
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powerful tool , but since we looked at proliferating T cells that expressed cytokines, we could 
have missed some cytokine producing cells that did not proliferate. 
In this chapter it was found that:  
(i) HEU infants produced a significantly higher frequency of IL-13 and IL-17 by CD4+ T cells at 
14 weeks of life in response to BCG. IL-17 is important and has been shown to populate the 
lungs, the primary site of Mycobacteria tuberculosis infections, and in turn recruit IFN-γ 
producing antigen-specific T cells persistent in the central lymphoid organs(Lin et al., 2011).   
HEU infants had significantly lower frequency of IL-13 production by CD8+ T cells compared 
to HU infants in response to BCG at 6 and 14 weeks of life, and of IL-17 production by CD8+ T 
cells in response to BCG at 14 weeks of age. The presence of these IL-13 producing cells at a 
significantly lower frequency may represent sub-optimal responses for protection from other 
viral infections, although the significance of IL-13 production by CD8 cells is not clear. Indeed, 
a significantly higher frequency of these infants presented with viral upper respiratory tract 
infections compared to their un-exposed counterparts (see table 2.1). However, it is not clear 
what these cytokines do in CD8+ T cells. (ii) No significant differences were observed between 
HEU and HU infants in the frequency of cytokine production by CD4+ and CD8+ T cells 
following BP and TT stimulation at 14 weeks of life, suggesting that cytokine responses to 
protein antigens are no different between the groups of infants (iii) HIV exposure was a major 
predictor of IL-17 production by CD8+ T cells in response to BCG longitudinally through time 
to 14 weeks after adjusting for other confounders presented by the cohort in the multivariate 
model, suggesting that cytokine response to live-attenuated bacterial antigens may be impaired. 
Consistent with findings by Mansoor et al., BCG vaccination of HIV-exposed infants induced a 
similar frequency of IFN-γ and IL-2 production by T cells compared to unexposed infants 
(Mansoor et al., 2010). The frequency of IFN-γ and IL-2 production by CD4+ T cells in response 
to BCG was similar in HEU versus HU infants at 6 and at 14 weeks of life in our study. HIV 
exposure as well as other confounders influenced cytokine production by T cells in response to 
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This is the first study to compare the intracellular cytokine response to tetanus and pertussis 
vaccinations in HEU versus HU infants. HIV exposure did not influence BP- and TT- induced 
cytokine production by T cells at 14 weeks of life.  
One limitation of this study is that we used PMA and Ionomycin as the intracellular cytokine 
staining (ICS) stimulation in the whole blood assay (WBA), so the cytokine producing T cells 
are derived from antigen specific responses, but were re-stimulated using PMA and Ionomycin 
which reflects the potential of the T cell to make cytokine, which has already expanded to the 
antigen in culture.    
In summary, the findings in this chapter suggest that HIV-exposure has subtle effects on 
cytokine responses to some antigens at 14 weeks but not at 6. The effect of HIV-exposure on 
cytokines may be age-dependant due to the ontogeny of the infants immune system generally and 
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6.1 Introduction 
This chapter aims to assess the proportions of proliferating CD4+ and CD8+ T lymphocytes in 
response to vaccine antigens [Bacillus Calmette-Guérin (BCG), Bordetella pertussis (BP) and 
Tetanus toxoids (TT)], and to SEB, expressing combinations of the following cytokines: IFN-γ, 
IL-2, IL-13 and/or IL-17, in HIV-exposed uninfected (HEU) versus HIV-unexposed (HU) 
infants at 6 and at 14 weeks of life.   
The frequency of cytokine production by antigen specific CD4+ and CD8+ T cells in HEU 
versus HU infants at 6 and at 14 weeks of life was measured after the ICS assay (described in the 
methods). Data after statistical analysis were presented as medians and interquatile ranges (IQR), 
alpha=0.05; statistical analysis was performed using Wilcoxon signed rank test (see table 3.3).   
This chapter addresses part of specific objective two, to compare the breadth of antigen specific 
CD4 and CD8 T cell intracellular cytokine production to BCG, BP and TT vaccine and SEB in 
HEU versus HU infants at 6 and 14 weeks of life. In Chapter 5 we compared the quality of 
antigen specific CD4 and CD8 T cell intracellular cytokine production to BCG, BP and TT 
vaccine and SEB antigen in HEU versus HU infants and the evolution of cytokine production to 
BCG and SEB from 6 to 14 weeks of life. In this chapter, proportions of cytokine producing cells 
of total proliferating cells are reported, whereas in the previous chapter, proliferating, cytokine-
producing cells were reported as the proportion of total T cells (see Figure 3.3).  
The different cytokines assessed have been described in section 1.3 and the role of these cytokine 
expressing T cells to provide insight into immunity to the vaccines has been described in sections 
1.5.2.2 and 5.1.   
 
6.2 Breadth of BCG-induced proliferating CD4+ and CD8+ T cell cytokine 
expression at 6 weeks of life in HEU versus HU infants 
(i)   BCG-CD4+ at week 6 
Figure 6.1 shows CD4+ T cell cytokine responses to BCG at 6 weeks. As seen in the graph, 
proportions of single cytokine producing CD4+ T cells, namely IL-13 (p=0.046) and IFN-γ 
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pies show that the overall cytokine production by CD4+ T cells was significantly lower in HEU 
compared to HU infants (p=0.0183) (Figure 6.1b). The difference in the proportion of CD4+ T 
cells that express no cytokines was evident and higher in HEU (Figure 6.1b).                                                                                                                    
(a)   
 
 (b)                                               
                                                     p=0.0183 
                                   
                 HEU                                         HU 
 
Figure 6.1: Breadth of BCG-induced proliferating CD4+ T cell cytokine production at 6 weeks of life 
in HEU versus HU infants. Comparison of the proportion of cells expressing no cytokine, one or a combination 
of IL-2, IFN-γ, IL-13 and IL-17 cytokine(s) by proliferating CD4+ T cells in HEU versus HU infants. (a) Represents 
the possible combination of the responses versus the proportions of the functionally distinct cell populations within 
the responding CD4+ T cells shown. Responses are grouped and colour-coded on the basis of the combinations of 
the cytokines produced. Spots correspond to the proportion of functionally distinct T cell populations within the 
proliferating CD4+ T cells (Each spot represents one infant). Error bars and whiskers correspond to medians and 
interquatile ranges (IQR) respectively; p-value indicates significant difference in the combination of cytokine 
production by CD4+ T cells between HEU versus HU infants. (b) The pie charts at the bottom summarise the data 
with the pie slice legend on the graph showing the colours of the various cytokine combinations and the p-value 
showing the overall significance of the total magnitude of the combinations of cytokine responses. (#) Alpha=0.05 
and Statistical analysis was performed using Wilcoxon signed rank test. 
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(ii)   BCG-CD8+ at week 6 
Figure 6.2 shows the breadth of the CD8+ T cell responses to BCG at 6 weeks. The top graph 
shows that the proportions of the dual cytokine IL-13/IL-17 (p=0.025) and the single cytokine 
IL-17 (p=0.033), production by CD8+ T cells at 6 weeks of age were significantly lower in HEU 
compared to HU infants. Conversely, the proportion of cells with no cytokine expression was 
significantly (p=0.018) higher in HEU infants (Figure 6.2a). The bottom pies show that the 
overall cytokine production by CD8+ T cells was significantly lower in HEU infants (p=0.0132) 
(Figure 6.2b). The difference of the proportion of CD8+ T cells that produce three cytokines was 
evident and lower in HEU infants (Figure 6.2b). 
(a)                                                                                                                                                                                
 
 (b)                     p=0.0132 
                                   
             HEU                                     HU 
Figure 6.2: Proportions of BCG-specific proliferating CD8+ T cells producing no cytokine, one, or a 
combination of cytokine(s) based on expression of IL-2, IFN-γ, IL-13 and/or IL-17, at 6 weeks of life in HEU 
versus HU infants. Comparison of the proportion of cells expressing no cytokine, one or a combination of 
intracellular cytokine(s) by proliferating CD8+ T cells in HEU versus HU infants. (a) Represents the possible 
combination of the responses shown versus the proportions of the functionally distinct cell populations within the 
Pie Legend 
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responding CD8+ T cells shown. Responses are grouped and colour-coded on the basis of the combinations of the 
cytokines produced. Spots correspond to the fractions of functionally distinct T cell populations within the 
proliferating CD8+ T cells. Error bars and whiskers correspond to medians and interquatile ranges (IQR) 
respectively; p-value indicates significant difference in the combination of cytokine production by CD8+ T cells 
between HEU versus HU infants. (b) The pie charts at the bottom summarise the data with the pie slice legend on 
the graph showing the colours of the various cytokine combinations and the p-value showing the overall significance 
of the total magnitude of the combinations of cytokine responses. (#) Alpha=0.05 and Statistical analysis was 
performed using Wilcoxon signed rank test. 
 
 
6.3 Breadth of BCG-induced proliferating CD4+ and CD8+ T cell cytokine 
expression at 14 weeks of life in HEU versus HU infants 
  (i)                BCG-CD4+ at week 14 
Figure 6.3 shows the breadth of CD4+ T cell cytokine responses to BCG at 14 weeks. As seen in 
the top graph, the proportions of CD4+ T cells producing IFN-γ alone at 14 weeks of age was 
significantly lower in HEU infants (p=0.008) (Figure 6.3a).  The bottom pies show that the 
overall breadth of cytokine production by CD4+ T cells at 14 weeks was significantly lower in 
HEU infants (p=0.0076) (Figure 6.3b).  
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 (b)                     p=0.0076 
                      
        HEU                                        HU 
       
Figure 6.3: Breadth of BCG-induced proliferating CD4+ T cell cytokine production at 14 weeks of 
life in HEU versus HU infants. Comparison of the proportion of cells expressing no cytokine, one or a 
combination of IL-2, IFN-γ, IL-13 and IL-17 cytokine(s) by proliferating CD4+ T cells in HEU versus HU infants. 
(a) Represents the possible combination of the responses shown versus the proportions of the functionally distinct 
cell populations within the responding CD4+ T cells shown. Responses are grouped and colour-coded on the basis 
of the combinations of the cytokines produced. Spots correspond to the fractions of functionally distinct T cell 
populations within the proliferating CD4+ T cells. Error bars and whiskers correspond to medians and interquatile 
ranges (IQR) respectively; p-value indicates significant difference in the combination of cytokine production by 
CD4+ T cells between HEU versus HU infants. (b) The pie charts at the bottom summarise the data with the pie 
slice legend on the graph showing the colours of the various cytokine combinations and the p-value showing the 
overall significance of the total magnitude of the combinations of cytokine responses. (#) Alpha=0.05 and Statistical 
analysis was performed using Wilcoxon signed rank test. 
 
(ii)                BCG-CD8+ at week 14 
 
Figure 6.4 shows the breadth of CD8+ T cell cytokine responses to BCG at 14 weeks. The top 
graph shows that the proportions of CD8+ T cells producing combinations of IL-2/IL-17 
(p=0.038) and IL-13/IL-17 (p=0.041) at 14 weeks were significantly lower in HEU infants at 14 
weeks of life (Figure 6.4a). The proportions of CD8+ T cells expressing single cytokines; IL-2 
(p=0.002) and IFN-γ (p=0.025) we e significantly higher in HEU infants (Figure 6.4a). Also, the 
proportion of CD8+ T cells that express no cytokine was significantly higher in HEU infants 
after BCG stimulation at 14 weeks of life (p=0.027) (Figure 6.4a). The bottom pies show that the 
overall proportion of cytokine production by CD8+ T cells was significantly lower in HEU 
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                               p=0.0106 
                   
        HEU                                          HU 
Figure 6.4: Proportions of BCG-specific proliferating CD8+ T cells producing no cytokine, one, or a 
combination of cytokine(s) based on expression of IL-2, IFN-γ, IL-13 and/or IL-17, at 14 weeks of life in HEU 
versus HU infants. Comparison of the proportion of cells expressing no cytokine, one or a combination of 
intracellular cytokine(s) by proliferating CD8+ T cells in HEU versus HU infants. (a) Represents the possible 
combination of the responses shown versus the proportions of the functionally distinct cell populations within the 
responding CD8+ T cells shown. Responses are grouped and colour-coded on the basis of the combinations of the 
cytokines produced. Spots correspond to the fractions of functionally distinct T cell populations within the 
proliferating CD8+ T cells. Error bars and whiskers correspond to medians and interquatile ranges (IQR) 
respectively; p-value indicates significant difference in the combination of cytokine production by CD8+ T cells 
between HEU versus HU infants. (b) The pie charts at the bottom summarise the data with the pie slice legend on 
the graph showing the colours of the various cytokine combinations and the p-value showing the overall significance 
of the total magnitude of the combinations of cytokine responses. (#) Alpha=0.05 and Statistical analysis was 
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These data shows that the breadth of cytokine expression by BCG specific CD4+ and CD8+ T 
cells was significantly lower in the HEU infants irrespective of the time point. The proportion of 
cytokine production by CD4+ T cells was mostly single cytokines, while the production of two 
or more cytokines did not show any significant difference between groups. Differences in the 
proportions of CD8+ T cells producing one or a combination of cytokine(s) responses were 
evident between the two infant groups. Single cytokine expressions by CD8+ T cells were 
significantly higher in HEU at 14 weeks with significantly lower dual cytokine expression. HIV-
exposure appears to markedly diminish the breath of cytokine production by T cells in response 
to BCG vaccination. 
 
6.4 Breadth of BP-induced proliferating CD4+ and CD8+ T cell cytokine 
production at 14 weeks of life in HEU versus HU infants 
 (i)  BP-CD4+ at week 14 
Bordetella pertussis vaccination is first administered at six weeks of life and boosted at 10 
weeks.  Therefore, proportions of proliferating CD4+ and CD8+ T cells that produced cytokines 
alone or in combination at 14 weeks of life were compared between HEU versus HU infants 
(Figure 6.5 and 6.6).  
 
Figure 6.5 shows the breadth of CD4+ T cell cytokine responses to BP at 14 weeks.  The top 
graph shows that at 14 weeks of age, no significant difference in the proportion of CD4+ T cells 
expressing one or a combination of cytokine(s) between HEU versus HU infants in response to 
BP was observed (Figure 6.5a). However, the proportion of CD4+ T cells that did not express 
any cytokine was significantly higher in HEU infants (p=0.001) (Figure 6.5a). The bottom pies 
show the breadth of proliferating CD4+ T cells cytokine expression was lower in HEU infants 
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(a)                                                                                                                          
 
 
 (b)                       p=0.0008 
                      
        HEU                                             HU 
Figure 6.5: Proportions of BP-specific proliferating CD4+ T cells producing no cytokine, one, or a 
combination of cytokine(s) based on expression of IL-2, IFN-γ, IL-13 and/or IL-17, at 14 weeks of life in HEU 
versus HU infants. Comparison of the proportion of cells expressing no cytokine, one or a combination of IL-2, 
IFN-γ, IL-13 and IL-17 cytokine(s) by proliferating CD4+ T cells in HEU versus HU infants. (a) Represents the 
possible combination of the responses shown versus the proportions of the functionally distinct cell populations 
within the responding CD4+ T cells shown. Responses are grouped and colour-coded on the basis of the 
combinations of the cytokines produced. Spots correspond to the proportions of functionally distinct T cell 
populations within the proliferating CD4+ T cells. Error bars and whiskers correspond to medians and interquatile 
ranges (IQR) respectively; p-value indicates significant difference in the combination of cytokine production by 
CD4+ T cells between HEU versus HU infants. (b) The pie charts at the bottom summarise the data with the pie 
slice legend on the graph showing the colours of the various cytokine combinations and the p-value showing the 
overall significance of the total magnitude of the combinations of cytokine responses. (#) Alpha=0.05 and Statistical 
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(ii)  BP-CD8+ at week 14 
Figure 6.6 shows the breadth of CD8+ T cell cytokine responses to BP at 14 weeks. It is evident 
from the top graph that the proportion of CD8+ T cells that expressed the cytokine IFN-γ alone 
was significantly lower in HEU infants in response to BP at 14 weeks of age (p=0.024) (Figure 
6.6a). No significant differences were observed in the proportions of CD8+ T cells that expressed 
more than one cytokine combination between HEU versus HU infants (Figure 6.6a). Also, the 
proportion of CD8+ T cells that expressed no cytokines was significantly higher in HEU infants 
(p=0.021) (Figure 6.6a). The bottom pies show that the difference in the overall proportion of 
cytokine expression by CD8+ T cells was significantly lower in HEU infants (p=0.0133) (Figure 
6.6b).  
(a)                                                                                                                              
 
 (b)                      p=0.0133 
                    
        HEU                                           HU 
Figure 6.6: Breadth of BP-induced proliferating CD8+ T cell cytokine production at 14 weeks of life 
in HEU versus HU infants. Comparison of the proportion of cells expressing no cytokine, one or a combination 
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of intracellular cytokine(s) by proliferating CD8+ T cells in HEU versus HU infants. (a) Represents the possible 
combination of the responses shown versus the proportions of the functionally distinct cell populations within the 
responding CD8+ T cells shown. Responses are grouped and colour-coded on the basis of the combinations of the 
cytokines produced. Spots correspond to the fractions of functionally distinct T cell populations within the 
proliferating CD8+ T cells. Error bars and whiskers correspond to medians and interquatile ranges (IQR) 
respectively; p-value indicates significant difference in the combination of cytokine production by CD8+ T cells 
between HEU versus HU infants. (b) The pie charts at the bottom summarise the data with the pie slice legend on 
the graph showing the colours of the various cytokine combinations and the p-value showing the overall significance 
of the total magnitude of the combinations of cytokine responses. (#) Alpha=0.05 and Statistical analysis was 
performed using Wilcoxon signed rank test. 
 
These data shows that in response to Bordetella pertussis at 14 weeks, there were no significant 
differences in the proportion of CD4+ T cells expressing one or a combination of cytokine(s) 
between HEU versus HU infants. However, a significant difference in the proportion of a mono-
functional cytokine production by CD8+ T cells was evident and significantly lower in HEU 
infants. HIV-exposure has a profound effect on breadth of cytokine production in response to BP 
vaccination.  
 
6.5 Breadth of TT-induced proliferating CD4+ and CD8+ T cell cytokine 
production at 14 weeks of life in HEU versus HU infants 
 (i)             TT-CD4+ at week 14 
The administration of Bordetella pertussis vaccination is in combination with Tetanus toxoid 
vaccination to infants in South Africa, first at six weeks of life and boosted at 10 weeks, so we 
measured antigen specific CD4+ and CD8+ T cells expression of no cytokines, one or a 
combination of cytokine(s) by CD4+ and CD8+ lymphocytes at 14 weeks of life between HEU 
versus HU infant (Figure 6.7 and 6.8).  
Figure 6.7 shows the breadth of the CD4+ T cell cytokine responses to TT at 14 weeks. The top 
graph shows that at 14 weeks of age, significant differences in the proportion of polyfunctional 
cytokine expressing cells by TT between HEU versus HU infants were not evident (Figure 6.7a). 
No significant difference was observed in the proportion of one or more cytokine expression by 
CD4+ T cells in response to TT between the two groups of infants (Figure 6.7a). The proportion 
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groups as observed from the graph (Figure 6.7a). Comparing the bottom pies, the overall 
cytokine expression by CD4+ T cells did not differ significantly between HEU and HU infants 
(p=0.1128) (Figure 6.7b).  
(a) 
 
 (b)                   p=0.1128 
                     
          HEU                                             HU 
Figure 6.7: Proportions of TT-specific proliferating CD4+ T cells producing no cytokine, one, or a 
combination of cytokine(s) based on expression of IL-2, IFN-γ, IL-13 and/or IL-17, at 14 weeks of life in HEU 
versus HU infants. Comparison of the proportion of cells expressing no cytokine, one or a combination of IL-2, 
IFN-γ, IL-13 and IL-17 cytokine(s) by proliferating CD4+ T cells in HEU versus HU infants. (a) Represents the 
possible combination of the responses shown versus the proportions of the functionally distinct cell populations 
within the responding CD4+ T cells shown. Responses are grouped and colour-coded on the basis of the 
combinations of the cytokines produced. Spots correspond to the fractions of functionally distinct T cell populations 
within the proliferating CD4+ T cells. Error bars and whiskers correspond to medians and interquatile ranges (IQR) 
respectively; p-value indicates significant difference in the combination of cytokine production by CD4+ T cells 
between HEU versus HU infants. (b) The pie charts at the bottom summarise the data with the pie slice legend on 
the graph showing the colours of the various cytokine combinations and the p-value showing the overall significance 
of the total magnitude of the combinations of cytokine responses. (#) Alpha=0.05 and Statistical analysis was 
performed using Wilcoxon signed rank test. 
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(ii)           TT-CD8+ at week 14 
 
Figure 6.8 shows the breadth of the CD8+ T cell responses to TT at 14 weeks. The top graph 
shows that the proportion of CD8+ T cells that expressed the single cytokine IL-17 was 
significantly higher in HEU infants (p=0.032) (Figure 6.8a). The proportion of CD8+ T cells that 
expressed more than one cytokine or no cytokine at all did not differ significantly between the 
two groups in response to TT at 14 weeks (Figure 6.8a). The pies at the bottom show that the 
proportion of cytokine expression by CD8+ T cells did not differ significantly between HEU 
versus HU infants (p=0.0759) (Figure 6.8b). However, a trend toward lower proportions of any 
two or more combination of cytokines expressed by CD8+ T cells, evident in HEU compared to 
their unexposed counterparts (Figure 6.8b).   
(a)                                                                                                                   
 
(b)                       p=0.0759 
                      
          HEU                                              HU 
Figure 6.8: Breadth of TT-induced proliferating CD8+ T cell cytokine production at 14 weeks of life 
in HEU versus HU infants. Comparison of the proportion of cells expressing no cytokine, one or a combination 
of intracellular cytokine(s) by proliferating CD8+ T cells in HEU versus HU infants. (a) Represents the possible 
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combination of the responses shown versus the proportions of the functionally distinct cell populations within the 
responding CD8+ T cells shown. Responses are grouped and colour-coded on the basis of the combinations of the 
cytokines produced. Spots correspond to the fractions of functionally distinct T cell populations within the 
proliferating CD8+ T cells. Error bars and whiskers correspond to medians and interquatile ranges (IQR) 
respectively; p-value indicates significant difference in the combination of cytokine production by CD8+ T cells 
between HEU versus HU infants. (b) The pie charts at the bottom summarise the data with the pie slice legend on 
the graph showing the colours of the various cytokine combinations and the p-value showing the overall significance 
of the total magnitude of the combinations of cytokine responses. (#) Alpha=0.05 and Statistical analysis was 
performed using Wilcoxon signed rank test. 
 
These results show that significant differences in response to TT were limited to the level of a 
single cytokine expression by CD8+ T cells,. It appears that the breadth of cytokine response to 
TT is less affected by HIV-exposure than the other vaccinations. 
 
6.6 Breadth of SEB-induced proliferating CD4+ and CD8+ T cell cytokine 
expression at 6 weeks of life in HEU versus HU infants 
 (i)             SEB-CD4+ at week 14 
Figure 6.9 shows the breadth of the CD4+ T cell responses to SEB at 6 weeks. The top graph 
shows that the proportion of CD4+ T cells that expressed the single cytokine IL-17 was 
significantly lower in HEU compared to HU infants (p=0.023)  (Figure 6.9a). The proportion of 
CD4+ T cells that expressed more than one cytokine or no cytokine at all did not differ 
significantly between the two groups in response to SEB at 6 weeks (Figure 6.9a). The pies at the 
bottom show that cytokine expression by CD4+ T cells did not differ significantly between HEU 
versus HU infants (p=0.1357) (Figure 6.9b) and there was a predominantly no cytokine 
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(a)                                                                                                                  
 
 (b)                       p=0.1357 
                                 
               HEU                                        HU 
Figure 6.9: Breadth of SEB-induced proliferating CD4+ T cell cytokine production at 6 weeks of life 
in HEU versus HU infants. Comparison of the proportion of cells expressing no cytokine, one or a combination 
of IL-2, IFN-γ, IL-13 and IL-17 cytokine(s) by proliferating CD4+ T cells in HEU versus HU infants. (a) Represents 
the possible combination of the responses shown versus the proportions of the functionally distinct cell populations 
within the responding CD4+ T cells shown. Responses are grouped and colour-coded on the basis of the 
combinations of the cytokines produced. Spots correspond to the fractions of functionally distinct T cell populations 
within the proliferating CD4+ T cells. Error bars and whiskers correspond to medians and interquatile ranges (IQR) 
respectively; p-value indicates significant difference in the combination of cytokine production by CD4+ T cells 
between HEU versus HU infants. (b) The pie charts at the bottom summarise the data with the pie slice legend on 
the graph showing the colours of the various cytokine combinations and the p-value showing the overall significance 
of the total magnitude of the combinations of cytokine responses. (#) Alpha=0.05 and Statistical analysis was 
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(ii)           SEB-CD8+ at week 6 
 
Figure 6.10 shows the breadth of CD8+ T cell cytokine responses to SEB at 6 weeks. The top 
graph shows that the proportions of CD8+ T cells expressing combinations of IL-2/IL-13 
(p=0.040) and IL-2/IFN-γ (p=0.042) at 6 weeks were significantly higher in HEU infants (Figure 
6.10a). The proportion of CD8+ T cells that expressed four cytokines, any combination of three 
cytokines, one cytokine or no cytokine at all did not differ significantly between the two groups 
in response to SEB at 6 weeks (Figure 6.10a). The pies show that the overall proportion of 
cytokine production by CD8+ T cells did not differ significantly between HEU versus HU 
infants (p=0.2570) (Figure 6.10b) with many cells unable to respond to SEB.  As with CD4+ 
cells, the majority of CD8+ T cells at six weeks made no cytokine, regardless of group. 
(a)                                                    
 
(b)                           p=0.2570 
                             
                 HEU                                      HU 
Figure 6.10: Proportions of SEB-specific proliferating CD8+ T cells producing no cytokine, one, or a 
combination of cytokine(s) based on expression of IL-2, IFN-γ, IL-13 and/or IL-17, at 6 weeks of life in HEU 
versus HU infants. Comparison of the proportion of cells expressing no cytokine, one or a combination of 
intracellular cytokine(s) by proliferating CD8+ T cells in HEU versus HU infants. (a) Represents the possible 
Pie Legend 
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combination of the responses shown versus the proportions of the functionally distinct cell populations within the 
responding CD8+ T cells shown. Responses are grouped and colour-coded on the basis of the combinations of the 
cytokines produced. Spots correspond to the fractions of functionally distinct T cell populations within the 
proliferating CD8+ T cells. Error bars and whiskers correspond to medians and interquatile ranges (IQR) 
respectively; p-value indicates significant difference in the combination of cytokine production by CD8+ T cells 
between HEU versus HU infants. (b) The pie charts at the bottom summarise the data with the pie slice legend on 
the graph showing the colours of the various cytokine combinations and the p-value showing the overall significance 
of the total magnitude of the combinations of cytokine responses. (#) Alpha=0.05 and Statistical analysis was 
performed using Wilcoxon signed rank test. 
 
6.7 Breadth of SEB-induced proliferating CD4+ and CD8+ T cell cytokine 
expression at 14 weeks of life in HEU versus HU infants 
(i)  SEB-CD4+ at week 14 
The proportion of CD4+ T cells that expressed the single cytokines IL-13 (p=0.003) and IFN-γ 
(p=0.005) were significantly lower in HEU infants (Figure 6.11a). The proportion of CD4+ T 
cells that expressed more than one cytokine did not differ significantly between the two groups 
in response to SEB at 14 weeks (Figure 6.11a). The proportion of CD4+ T cells that did not 
express any cytokine was significantly higher in HEU infants after SEB stimulation at 14 weeks 
of life (p<0.001) (Figure 6.11a). Similar to the findings at 6 weeks of age, the breadth of the 
CD4+ T cell responses to SEB at 14 weeks regardless of group was low and mostly made no 
cytokine at all, however HEU infants had significantly lower breadth (p=0.0015) (Figure 6.11b). 
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 (b)                              P=0.0015 
                                         
                       HEU                                      HU 
 Figure 6.11: Breadth of SEB-induced proliferating CD4+ T cell cytokine production at 14 weeks of 
life in HEU versus HU infants. Comparison of the proportion of cells expressing no cytokine, one or a 
combination of IL-2, IFN-γ, IL-13 and IL-17 cytokine(s) by proliferating CD4+ T cells in HEU versus HU infants. 
(a) Represents the possible combination of the responses shown versus the proportions of the functionally distinct 
cell populations within the responding CD4+ T cells shown. Responses are grouped and colour-coded on the basis 
of the combinations of the cytokines produced. Spots correspond to the fractions of functionally distinct T cell 
populations within the proliferating CD4+ T cells. Error bars and whiskers correspond to medians and interquatile 
ranges (IQR) respectively; p-value indicates significant difference in the combination of cytokine production by 
CD4+ T cells between HEU versus HU infants. (b) The pie charts at the bottom summarise the data with the pie 
slice legend on the graph showing the colours of the various cytokine combinations and the p-value showing the 
overall significance of the total magnitude of the combinations of cytokine responses. (#) Alpha=0.05 and Statistical 
analysis was performed using Wilcoxon signed rank test. 
 
 
(ii)  SEB-CD8+ at week 14 
 
Figure 6.12 shows the breadth of CD8+ T cell cytokine responses to SEB at 14 weeks. The top 
graph shows that the proportions of CD8+ T cells expressing combinations of IL-13/IL-17/IFN-γ 
at 14 weeks of life were significantly lower in the HEU compared to their unexposed 
counterparts (p=0.001) (Figures 12a). The proportions of CD8+ T cells expressing two 
combinations of IL-13/IL-17 (p=0.039) and one cytokine IFN-γ (p=0.008) at 14 weeks were 
significantly lower in HEU infants (Figure 6.12a). Conversely, the proportion of CD8+ T cells 
that could not express any cytokine was significantly higher in HEU infants after SEB 
stimulation at 14 weeks of life (p<0.001) (Figure 6.12a). The bottom pies show that the overall 
proportion of cytokine expression by CD8+ T cells in HU was higher than at 6 weeks, but HEU 
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(a)                                
 
(b)                          P<0.0001 
                             
                 HEU                                     HU 
                                                                                                                                                                      
Figure 6.12: Proportions of SEB-specific proliferating CD8+ T cells producing no cytokine, one, or a 
combination of cytokine(s) based on expression of IL-2, IFN-γ, IL-13 and/or IL-17, at 14 weeks of life in HEU 
versus HU infants. Comparison of the proportion of cells expressing no cytokine, one or a combination of 
intracellular cytokine(s) by proliferating CD8+ T cells in HEU versus HU infants. (a) Represents the possible 
combination of the responses shown versus the proportions of the functionally distinct cell populations within the 
responding CD8+ T cells shown. Responses are grouped and colour-coded on the basis of the combinations of the 
cytokines produced. Spots correspond to the fractions of functionally distinct T cell populations within the 
proliferating CD8+ T cells. Error bars and whiskers correspond to medians and interquatile ranges (IQR) 
respectively; p-value indicates significant difference in the combination of cytokine production by CD8+ T cells 
between HEU versus HU infants. (b) The pie charts at the bottom summarise the data with the pie slice legend on 
the graph showing the colours of the various cytokine combinations and the p-value showing the overall significance 
of the total magnitude of the combinations of cytokine responses. (#) Alpha=0.05 and Statistical analysis was 
performed using Wilcoxon signed rank test. 
 
These data show that, the breadth of cytokine production by proliferating T cells in response to 
SEB was significantly lower in the HEU infants irrespective of the time points. Significant 
differences in the proportion of cytokine production by CD4+ T cells was mostly single 
cytokines, while the production of two or more cytokines was evident by CD8+ T cells. Many 
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cells were unable to respond to SEB, the lack of responsiveness could indicate cell anergy due to 
an over whelming stimulation by SEB on infants cells. These data mean that in utero HIV-
exposure could affect responses to in vitro stimulation as well as recall antigens.  
  
6.8 Result summary 
Table 6.1 illustrates that in general, the breadth of cytokine production by proliferating CD4+ T 
cells was significantly lower in the HEU infants irrespective of the time points or vaccine antigen 
stimulation. The proportion of cytokine production by CD4+ T cells was mostly single 
cytokines, while the production of two or more cytokines did not show any significant difference 
between groups.   
Differences in the proportions of proliferating CD8+ T cells producing one or a combination of 
cytokine(s) responses were evident between the two infant groups. The proportion of CD8+ T 
cells producing two or more cytokines in response to BCG was significantly lower in the HEU 
infants, at 6 and 14 weeks, (Table 6.1). However, in response to SEB the production of dual 
cytokine combinations of IL-2/IL-13 and IL-2/IFN-γ by CD8+ T cells at 6 weeks was 
significantly higher in HEU compared to HU infants (Table 6.1).     
In response to Bordetella pertussis and Tetanus toxoids at 14 weeks, significant differences in 
the proportion of proliferating CD4+ T cells producing one or a combination of cytokine(s) 
between HEU versus HU infants were not evident. However, a significant difference in the 
proportion of mono-functional cytokine production by CD8+ T cells was evident (Table 6.1). 
Significant differences were limited to the level of single cytokine production by CD8+ T cells, 
while significantly lower in HEU infants in response to BP; it was significantly higher in HEU 
infants in response to TT (Table 6.1). 
Also, proportions of CD4+ and CD8+ T cells that could not produce cytokine upon antigen 
stimulation were significantly higher in the HEU infant group irrespective of the antigen 
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These results are somewhat consistent with that observed in chapter five. There was a mixed 
effect in the quality of cytokine production in response to BCG. HEU infants had significantly 
lower frequencies of IL-13 production by CD8+ T cells compared to HU infants at 6 and 14 
weeks of life, and of IL-17 production by CD8+ T cells at 14 weeks of age. However, HEU 
infants produced a significantly higher frequency of IL-13 and IL-17 by CD4+ T cells at 14 
weeks of life. Similar findings were also observed in the breadth of cytokine production. 
Differences in the proportions of CD8+ T cells producing one or a combination of cytokine(s) 
responses were evident between the two infant groups. Single cytokine expressions by CD8+ T 
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Table 6.1: Significant differences in the proportion of proliferating CD4+ and CD8+ T cells expressing no 
cytokine, one or a combination of cytokine(s) in HEU versus HU infants at 6 and 14 weeks of life. Vaccine 
antigen i.e. Bacillus Calmette-Guérin (BCG), Bordetella pertussis (BP) and Tetanus toxoid (TT) proportion of T cells 
expressing no cytokine, one or a combination of cytokine(s) i.e. IFN-γ, IL-2, IL-13 and/or IL-17 in HEU versus HU 
infants at 6 and 14 weeks of life. Parameters include read outs for each condition and time point (TP), p values 
between pie charts and points on the graph of HEU versus HU infants proportions of proliferating CD4+ and CD8+ T 
cells expressing no cytokine, one or a combination of cytokine(s). Cells on the table indicated N/A represents not 
applicable, since BP* and TT* are administered to infants in DTaP vaccine, with the first dose given (primed) at 6 
weeks and NS represents no significant difference(s).   
CYTOKINE COMBINATIONS SIGNIFICANTLY LOWER IN HEU INFANTS 
Parameters p-values HEU vs. HU bars  











Week 6 -N/A -N/A 
Week 14  -IFN-γ 
TT 
Week 6 -N/A -N/A 
Week 14 -(NS)  
SEB 







CYTOKINE COMBINATIONS SIGNIFICANTLY HIGHER IN HEU INFANTS 
Parameters HEU vs. HU bars  
Condition TP CD4+ CD8+ 
BCG 
Week 6  -No cytokine 





Week 6 -N/A -N/A 
Week 14 -No cytokine -No cytokine 
TT 
Week 6 -N/A -N/A 
Week 14 -(NS) IL-17 
SEB 
Week 6  
-IL-2/IL-13 
-IL-2/IFN-γ 
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6.9 Discussion 
Overall, the proportion of vaccine antigen stimulated CD4+ and CD8+ T cells that respond to in 
vitro culture were significantly less polyfunctional in the HEU compared to the HU infants at 
both time points when comparing all the cytokine combinations.  
The presence of polyfunctional T cells may be a representative of the quality of immune 
responses to vaccines and has been described to be associated with better clinical 
prognosis(John-stewart et al., 2009)(Kagina et al., 2009)(Burl et al., 2012).  Darrah et al., 
showed that polyfunctional T cells expressing IFN-γ/IL-2/TNF-α correlate with vaccine 
mediated protection against Leishmania major(Darrah et al., 2007). Polyfunctional T cells have 
been associated with long term control of HIV infection (Betts et al., 2008). Polyfunctional 
responses to MTB distinguish latent infection versus active disease(Day et al., 2012). Hence, 
HIV-exposure may negatively affect the response to certain antigens and vaccinations and may 
contribute to the increased morbidity and increased risk of TB disease(Hesseling et al., 2010) of 
this vulnerable group. 
On the other hand, after ex vivo stimulation with SEB, combinations of dual cytokine production 
by CD8+ cells were significantly higher in HEU infants at 6 weeks, but not observed in response 
to BCG. This may be due to the nature of the assay and antigens. The assay measured recall 
responses to BCG, a live replicating bacterial vaccine, whereas SEB responses were merely 
reflective of in vitro rather than in vivo TCR stimulation. Also, as suggested in chapter 4 (see 
discussion), it may be that BCG in vivo after vaccination selects for specific Vβ TCR families 
which expand and respo d better to SEB in the whole blood assay. Also, HIV-exposure may 
expand (or delete) specific T cell clones i.e. Vβ TCR that are further expanded by SEB at a later 
time point (i.e. 14 weeks not 6) but respond in vivo to BCG in the assay. 
It is vital to identify deficiencies of the immune system and their contribution to the increased 
morbidity seen in HEU infants, both to improve their morbidity and to inform vaccine design. It 
will also be important to measure the breadth of other cytokines that were not examined in this 
dissertation. It is possible that cells that appeared to not make any cytokine were in fact making 
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to vaccines at an early age in the HEU infant may be due to exposure to maternal HIV and may 
influence the development of subsequent cellular as well as innate and adaptive immune 

















Infectious diseases account for nearly six million deaths annually worldwide in children younger 
than five years. Immunization against vaccine-preventable infections is essential and cost 
effective in reducing childhood morbidity and mortality. Deficiencies of both innate and adaptive 
immunity in neonates and infants render them more susceptible to infectious diseases.  
Due to the tolerant and complex nature of T cell immunity in neonates and infants, priming 
neonatal T cells is challenging and neonatal and infants T cell responses are biased towards T 
helper type-2 (Th2), thus complicating the induction of protective immune responses by 
vaccines(Jaspan et al., 2007)(Siegrist, 2007). 
An estimated two million infants are exposed in utero to Human Immuno Deficiency Virus 
(HIV) world wide of which about a third acquires HIV and an estimated two thirds are HIV-
uninfected, known as HIV-exposed uninfected (HEU) infants. These infants have higher 
morbidity and mortality despite being HIV-uninfected, and independent of their maternal disease 
stage(Mbori-ngacha et al., 2001). It is unclear whether this increased vulnerability is due to 
dysfunctional immunological responses, rendering the infant open to underlying pathogen insult.  
There are some documented immunological differences in HEU infants (section 1.5.1). This 
susceptible group of infants are exposed to low-dose of HIV-1 associated with the development 
of T helper type-1 responses(Kuhn et al., 2002). Some evidence suggests that they may have 
altered vaccine and mitogen responses(Van Rie et al., 2006)(Jones, 2011)(Mazzola et al., 2011) 
In addition, to the already observed altered immune features of the HEU infants, this dissertation 
has shown that; 
 (i) HIV-exposure can alter proliferative immune responses to some antigens at 14 weeks but not 
6. These include significantly higher CD8+ T cell proliferation to BCG and both CD4+ and 
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(ii) HIV-exposure diminishes the frequency of CD8+ T cell cytokines (IL-17 and IL-13)
responses to BCG at 14 weeks (not at 6 weeks), but no significant difference to other antigens 
(BP, TT, and SEB).  
(iii) Overall, magnitude and breadth of cytokine response to vaccines antigens were significantly
lower in HEU infants irrespective of age examined. 
Some differences were evident in the finding obtained between chapter 5 and chapter 6 in the 
single cytokine results. In response to BP, expression of IFN-γ by CD8+ T cells was significantly
lower in HEU infants, and BCG-induced IFN-γ and IL-2 at 14 weeks were significantly higher in
HEU infants in the breadth by proliferating T cells in Chapter 6, but not different in the quality
of cytokine production reported in Chapter 5. Both Chapters are reporting different data, because
the denominators differ. The data reported in Chapter 5 was dependant on the proliferation
response (antigen-specific) T cells reported as a frequency of total CD4+ and CD8+
lymphocytes. Whereas Chapter 6 was not, and the data was reported as proportions of cytokine
producing cells of total proliferating cells. 
The importance of reporting the data as in Chapter 5 is that, when just looking at the frequency
of Ki67+ cells that are IFN-γ+, the numbers were misleading, where the negative control sample
(medium) would have for instance 10% positive but when it was only a single cell out of 10. So
reporting the data as a frequency of total CD4+ and CD8+ T cells was a more appropriate 
comparison, since the denominators will be more consistent. Otherwise, when looking at the 
frequency of Ki67+ cells secreting IFN-γ, not only the numerator (i.e. the number of Ki67+ cells 
secreting IFN-γ) was dependent on the antigen stimulations, but also was the denominator (i.e.
the number of Ki67+ cells).
 Also, another reason why Chapter 6 was presenting with more significant differences as 
compared with Chapter 5 was because cells that were making no cytokine were also reported, 
which provided a very important piece of information. It seemed that HIV-exposure profoundly 
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This was an observational study, the effect on immune responses by potential confounders such 
as birth weight, weight and age at the time of visit, in addition to HIV-exposure, was considered. 
HIV-exposure inversely predicted CD8+ T cell proliferation in response to Tetanus toxoid 
stimulation at 14 weeks of life after correcting for these other confounders (Table 4.2), and did 
not predict single cytokine production by T cells in response to any vaccine antigen.  
However, over time from 6 to 14 weeks of age, HIV-exposure positively predicted and was the 
most important determinant of CD4+ T cell proliferation in response to BCG and SEB 
stimulations (Table 4.2); and positively predicted IFN-γ production by CD4+ T cells in response 
to BCG longitudinally over time to 14 weeks of life after correcting for other confounders in 
multivariate analyses.   
The results from this dissertation show that HIV-exposure significantly affects CD4+ T cell 
proliferation to live, attenuated bacterial antigen (BCG) from 6 to 14 weeks of life over time. It 
would be very important to conduct future studies on cellular immune responses over prolonged 
follow-up periods greater than 14 weeks of life to determine the evolution of T cell functions (i.e. 
proliferation and cytokine production). Comparisons such as these could inform timing and 
design of vaccines for HEU infants.  
Further, the lack of or low level responsiveness to BP and TT at 14 weeks compared to BCG 
may be due to the time intervals between immunization and blood sampling, not due to intrinsic 
factors related to the immune system of infants. Studies are currently going on looking at further 
time points and with a larger sample size. A series of ex vivo stimulations and the 6 days culture 
period may also not reflect in vivo responses. Many activated cells, when re-stimulated, may 
undergo activation induced cell death (apoptosis), and thus will not be reported for the final read 
out. Lastly, the potential effects of antiretroviral (ARV) for prevention of mother to child 
transmission (PMTCT) of HIV on the HEU arm, not present in the HU arm is strongly 
acknowledged. ARVs can affect the infants in utero and postpartum and are an uncontrolled 
factor of unknown significance. As a limitation of the study, we did not have data for complete 
blood count (CBC) at these time points to record variation in infant WBC count. One might 
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added to the cultures, rather than a fixed cell count. This would be a factor to correct for in future 
studies. However, we also acquired a fix amount of cells with an average of 200,000 cells per 
acquisition, and all data was presented as frequency of lymphocytes not as absolute numbers. 
Understanding T cell proliferation, cytokine milieu, dose and nature of the antigen (systemic or 
mucosal pathogen) as well as other neonatal immunological characteristics of HEU infants 
[impact of Regulatory T Cells (Tregs) and other suppressor cell populations such as Myeloid 
Derived Suppressor Cells (MDSCs) on vaccine immunity], may contribute to developing more 
effective vaccination strategies.  
The additional advantage to studying the immune response of HEU infants is the knowledge
gained as a controlled model for highly exposed uninfected individuals. A number of cohorts 
exist among populations at high risk of acquiring HIV, including HIV serodiscordant couples,
commercial sex workers and injection drug users. With the absence of an effective HIV vaccine, 
the HEU infants provide a unique model for studying not only the consequences of early
antigenic exposure in infants, but also provide very important insights for the study of immune 
correlates of protection to HIV and HIV-vaccine development.
The knowledge gained in this study will assist in designing studies in future to address the effect
of HIV-exposure on mucosal vaccines [oral polio vaccine (OPV) and rotavirus vaccine (RV)]














Appendix A: Analysis within feeding and HIV-exposure mode to assess the effect of 
birth feeding mode on T cell responses.  
Due to the fact that birth feeding mode was highly collinear with HIV-exposure status, subgroup 
analysis (i.e. analyses within groups of similar infants only) were also performed. Because the 
sample sizes of these groups were then very small, p-values were ignored and instead, 2-fold 
differences between medians (i.e. log order) was considered to reflect a meaningful difference in 
T cell proliferation. See table A1 in a few pages ahead that presents a summary of the graphs 
below.  
It was found that; 
(i) Exclusively breastfed (EBF) HU show better T cell proliferation at 6 weeks compared to the 
EBF HEU infants but vice versa at 14 weeks in response to SEB (Figure A1). Also, EBF HEU at 
6 weeks had better T cell proliferation than HU infants in response to BCG but similar levels at 
14 weeks (Figure A1). (ii) All mixed fed (MF) HEU show better T cell proliferation at both 6 
and 14 weeks compared to the MF HU infants at both 6 and 14 weeks of life in response to BCG 
and SEB (Figure A2). (iii) EBF infants in both the HEU and HU groups show better T cell 
proliferation compared to the MF infants in response to BCG at 6 weeks of age (Figure A3). (iv) 
EBF infants in both the HEU and HU groups show better T cell proliferation at 6 compared to 14 
weeks of life in response to BCG and SEB (Figure A4). (v) MF HU infants show better T cell 
proliferation at 6 compared to 14 weeks of life in response to SEB (Figure A5). 
Therefore, feeding mode could confound the relationship between HIV-exposure and vaccine 
responsiveness.  
  
Similar to the observation by Pabst et al. where they described the positive influence of breast 
feeding on cell mediated immune responses to BCG vaccine given at birth by measuring antigen-
induced blastogenesis in infants lymphocytes in response to purified protein derivative of 












(i) Exclusively breastfed (EBF) HU show better T cell proliferation at 6
weeks compared to the EBF HEU infants but vice versa at 14 weeks.
A. BCG Stimulation
B. SEB Stimulation
Figure A1: Frequency of proliferating T cells after (A) Bacillus Calmette-Guérin [BCG] and (B) 
Staphylococcal enterotoxin B [SEB] stimulation of exclusively breastfed (EBF) HU infants compared to 
the EBF HEU infants for 6 days in a whole blood assay at 6 and 14 weeks of life measured by flow 
cytometry. Frequency of CD4+ (CD8-) (filled ovals and triangles on the left side of each graph) and CD8+ 
(open ovals and triangles on the right side of each graph) proliferating T cells determined by flow cytometry in 
BCG-stimulated whole blood of HIV-exposed uninfected infants (HEU: ovals) presented on the left of each side 
of the plot compared to HIV-unexposed infants (HU: triangles) presented on the right of each side of the plot at 6 
and at 14 weeks of life. Bars indicate medians; p<0.05 significant level and statistical significance was obtained 











(ii) All mixed fed (MF) HEU show better T cell proliferation at both 6 and 14 weeks
compared to the MF HU infants at both 6 and 14 weeks of life.
A. BCG Stimulation
B. SEB Stimulation
Figure A2: Frequency of proliferating T cells after (A) Bacillus Calmette-Guérin [BCG] and (B)
Staphylococcal enterotoxin B [SEB] stimulation of mixed fed (MF) HU infants compared to the MF
HEU infants for 6 days in a whole blood assay at 6 and 14 weeks of life measured by flow cytometry.
Frequency of CD4+ (CD8-) (filled ovals and triangles on the left side of each graph) and CD8+ (open ovals and
triangles on the right side of each graph) proliferating T cells determined by flow cytometry in BCG-stimulated
whole blood of HIV-exposed uninfected infants (HEU: ovals) presented on the left of each side of the plot 
compared to HIV-unexposed infants (HU: triangles) presented on the right of each side of the plot at 6 and at 14
weeks of life. Bars indicate medians; p<0.05 significant level and statistical significance was obtained using
Mann-Whitney U test.
(iii) EBF infants in both the HEU and HU groups show better T cell proliferation













Figure A3: Frequency of proliferating T cells after (A) Bacillus Calmette-Guérin [BCG] and (B)
Staphylococcal enterotoxin B [SEB] stimulation of HU and HEU infants T cells proliferation in exclusively
breastfed (EBF) compared to mixed fed (MF) infants of the same group for 6 days in a whole blood assay
at 6 and 14 weeks of life measured by flow cytometry. Frequency of CD4+ (CD8-) (filled ovals and triangles
on the left side of each graph) and CD8+ (open ovals and triangles on the right side of each graph) proliferating
T cells determined by flow cytometry in BCG-stimulated whole blood of HIV-exposed uninfected infants (HEU:
ovals) presented on the left of each side of the plot compared to HIV-unexposed infants (HU: triangles) 
presented on the right of each side of the plot at 6 and at 14 weeks of life. Bars indicate medians; p<0.05
significant level and statistical significance was obtained using Mann-Whitney U test.
(iv) EBF infants in both the HEU and HU groups show better T cell proliferation at 6













Figure A4: Frequency of proliferating T cells after (A) Bacillus Calmette-Guérin [BCG] and (B) 
Staphylococcal enterotoxin B [SEB] stimulation of exclusively breastfed (EBF) HU and HEU infants for 6 
days in a whole blood assay at 6 and 14 weeks of life measured by flow cytometry. Frequency of CD4+ 
(CD8-) (filled ovals and triangles on the left side of each graph) and CD8+ (open ovals and triangles on the right 
side of each graph) proliferating T cells determined by flow cytometry in BCG-stimulated whole blood of HIV-
exposed uninfected infants (HEU: ovals) presented on the left of each side of the plot compared to HIV-
unexposed infants (HU: triangles) presented on the right of each side of the plot at 6 and at 14 weeks of life. Bars 
indicate medians; p<0.05 significant level and statistical significance was obtained using Mann-Whitney U test.   













Figure A5: Frequency of proliferating T cells after (A) Bacillus Calmette-Guérin [BCG] and (B) 
Staphylococcal enterotoxin B [SEB] stimulation of mixed fed (MF) HU and HEU infants for 6 days in a 
whole blood assay at 6 and 14 weeks of life measured by flow cytometry. Frequency of CD4+ (CD8-) (filled 
ovals and triangles on the left side of each graph) and CD8+ (open ovals and triangles on the right side of each 
graph) proliferating T cells determined by flow cytometry in BCG-stimulated whole blood of HIV-exposed 
uninfected infants (HEU: ovals) presented on the left of each side of the plot compared to HIV-unexposed infants 
(HU: triangles) presented on the right of each side of the plot at 6 and at 14 weeks of life. Bars indicate medians; 
p<0.05 significant level and statistical significance was obtained using Mann-Whitney U test.   











Table A1: Ignoring p-values considering 2-fold differences (i.e. log order) to reflect a meaningful 
difference in CD4 and CD8 T cell proliferation.  
Aspect Parameter Condition CD4+ CD8+ 
(i) All EBF
(HEU vs. HU) 
Week 6 A. SEB HU > HEU 
Week 14 A. SEB HEU > HU HEU > HU 
(ii) All MF
(HEU vs. HU) 





HEU > HU 
HEU > HU 
HEU > HU 
(iii) HEU
(EBF vs. MF) 
Week 6 
A. BCG EBF > MF EBF > MF 
A. BCG EBF > MF  HU 
(EBF vs. MF) 
Red highlights indicate week 6 
Blue highlights indicate week 14   
Green highlights indicate evolution of CD4 and CD8 responses from 6 to 14 weeks of life. 
 HEU=HIV exposed uninfected; HU= HIV unexposed
 Comparing all Exclusively Breastfed (EBF) only; HEU vs. HU 
 Comparing all Mixed fed (MF) only; HEU vs. HU
 Comparing EBF vs. MF considering HEU & HU Infants separately
 Within EBF only  comparing 6 vs. 14 Weeks











Appendix B: Ignoring p-values considering 2-fold differences (i.e. log order) to reflect
a meaningful difference in T cell IFN-γ secreting cells.  
Also, analysis where p-values were assessed based on 2-fold differences between medians (i.e. 
log order) to reflect a meaningful difference in T cell IFN-γ secreting cells was done.  
(i) Exclusively breastfed (EBF) HU had better IFN-γ expression by T cells at 6 weeks compared
to the EBF HEU infants (Figure B1). (ii) However, most mixed fed (MF) HEU had better IFN-γ
expression by T cells at both 6 and 14 weeks compared to the MF HU infants at both 6 and 14
weeks of life to BCG, except for SEB stimulation at 14 weeks of life (Figure B2). (iii) MF
infants in the HEU groups had better IFN-γ expression by T cells compared to the EBF infants at
6 weeks of life but not at 14 weeks in response to BCG (Figure B3); but EBF infants in the HU
group showed better IFN-γ expression by T cells compared to the MF infants at 6 weeks of life
(Figure B3). In response to SEB the levels of IFN-γ production did not differ (Figure B3). (iv)
EBF infants in both the HEU and HU groups had better IFN-γ expression by T cells at 6
compared to 14 weeks of life in response to BCG and SEB (Figure B4). (v) MF HU infants had 
better IFN-γ expression by CD4+ T cells at 6 compared to 14 weeks of life and by CD8+ T cells 
in response to SEB, but better IFN-γ expression by CD8+ T cells at 14 compared to 6 weeks of 
life in response to BCG (Figure B5). See table B1 in a few pages ahead that presents a summary











(i) Exclusively breastfed (EBF) HU show better IFN-γ expression by T cells at 6 weeks
compared to the EBF HEU infants.
A. BCG Stimulation (IFN-γ)
B. SEB Stimulation (IFN-Ƴ )
Figure B1: The frequency of T cells producing IFN-γ after (A) Bacillus Calmette-Guérin [BCG] and (B) 
Staphylococcal enterotoxin B [SEB] stimulation of exclusively breastfed (EBF) HU infants compared to 
the EBF HEU infants for 6 days in a whole blood assay at 6 and 14 weeks of life measured by flow 
cytometry. Frequency of CD4+ (CD8-) (filled ovals and triangles on the left side of each graph) and CD8+ 
(open ovals and triangles on the right side of each graph) proliferating T cells determined by flow cytometry in 
BCG-stimulated whole blood of HIV-exposed uninfected infants (HEU: ovals) presented on the left of each side 
of the plot compared to HIV-unexposed infants (HU: triangles) presented on the right of each side of the plot at 6 
and at 14 weeks of life. Bars indicate medians; p<0.05 significant level and statistical significance was obtained 











(ii) All mixed fed (MF) HEU show better IFN-γ expression by T cells at both 6 and 14
weeks compared to the MF HU infants at both 6 and 14 weeks of life, except for SEB
stimulation at 14 weeks of life.
A. BCG Stimulation (IFN-γ)
B. SEB Stimulation (IFN-γ)
Figure B2: The frequency of T cells producing IFN-γ after (A) Bacillus Calmette-Guérin [BCG] and (B) 
Staphylococcal enterotoxin B [SEB] stimulation of mixed fed (MF) HU infants compared to the MF 
HEU infants for 6 days in a whole blood assay at 6 and 14 weeks of life measured by flow cytometry. 
Frequency of CD4+ (CD8-) (filled ovals and triangles on the left side of each graph) and CD8+ (open ovals and 
triangles on the right side of each graph) proliferating T cells determined by flow cytometry in BCG-stimulated 
whole blood of HIV-exposed uninfected infants (HEU: ovals) presented on the left of each side of the plot 
compared to HIV-unexposed infants (HU: triangles) presented on the right of each side of the plot at 6 and at 14 
weeks of life. Bars indicate medians; p<0.05 significant level and statistical significance was obtained using 











(iii) MF infants in the HEU groups show better IFN-γ expression by T cells compared to
the EBF infants at 6 weeks of life but not at 14 weeks; but EBF infants in the HU group
showed better IFN-γ expression by T cells compared to the MF infants at 6 weeks of life.
A. BCG Stimulation (IFN-γ)
B. SEB Stimulation (IFN-γ)
Figure B3: The frequency of T cells producing IFN-γ after (A) Bacillus Calmette-Guérin [BCG] and (B) 
Staphylococcal enterotoxin B [SEB] stimulation of HU and HEU infants T cells IFN-Ƴ  production in 
exclusively breastfed (EBF) compared to mixed fed (MF) infants of the same group for 6 days in a whole 
blood assay at 6 and 14 weeks of life measured by flow cytometry. Frequency of CD4+ (CD8-) (filled ovals 
and triangles on the left side of each graph) and CD8+ (open ovals and triangles on the right side of each graph) 
proliferating T cells determined by flow cytometry in BCG-stimulated whole blood of HIV-exposed uninfected 
infants (HEU: ovals) presented on the left of each side of the plot compared to HIV-unexposed infants (HU: 
triangles) presented on the right of each side of the plot at 6 and at 14 weeks of life. Bars indicate medians; 











(iv) EBF infants in both the HEU and HU groups show better IFN-γ expression by T cells
at 6 compared to 14 weeks of life.
A. BCG Stimulation (IFN-γ)
B. SEB Stimulation (IFN-γ)
Figure B4: The frequency of T cells producing IFN-γ after (A) Bacillus Calmette-Guérin [BCG] and (B) 
Staphylococcal enterotoxin B [SEB] stimulation of exclusively breastfed (EBF) HU and HEU infants for 6 











(CD8-) (filled ovals and triangles on the left side of each graph) and CD8+ (open ovals and triangles on the right 
side of each graph) proliferating T cells determined by flow cytometry in BCG-stimulated whole blood of HIV-
exposed uninfected infants (HEU: ovals) presented on the left of each side of the plot compared to HIV-
unexposed infants (HU: triangles) presented on the right of each side of the plot at 6 and at 14 weeks of life. Bars 
indicate medians; p<0.05 significant level and statistical significance was obtained using Mann-Whitney U test.   
(v) MF HU infants show better IFN-γ expression by CD4+ T cells at 6 compared to 14
weeks of life and by CD8+ T cells in response to SEB, but better IFN-γ expression by
CD8+ T cells at 14 compared to 6 weeks of life in response to BCG.











B. SEB Stimulation (IFN-γ)
Figure B5: The frequency of T cells producing IFN-γ after (A) Bacillus Calmette-Guérin [BCG] and (B)
Staphylococcal enterotoxin B [SEB] stimulation of mixed fed (MF) HU and HEU infants for 6 days in a 
whole blood assay at 6 and 14 weeks of life measured by flow cytometry. Frequency of CD4+ (CD8-) (filled
ovals and triangles on the left side of each graph) and CD8+ (open ovals and triangles on the right side of each
graph) proliferating T cells determined by flow cytometry in BCG-stimulated whole blood of HIV-exposed
uninfected infants (HEU: ovals) presented on the left of each side of the plot compared to HIV-unexposed infants
(HU: triangles) presented on the right of each side of the plot at 6 and at 14 weeks of life. Bars indicate medians; 











Table B1 below presents a summary of the data presented on the graphs above. 
Table B1: Ignoring p-values considering 2-fold differences (i.e. log order) to reflect a meaningful difference 
in T cell IFN-γ secreting cells.  
Aspect Parameter Condition CD4+ CD8+ 
All EBF 




HU > HEU 
HU > HEU 
All MF 





HEU > HU 
HEU > HU 




HEU > HU 
HU > HEU 
HEU 





MF > EBF 
MF > EBF 
MF > EBF 
MF > EBF 
HU 
(EBF vs. MF) 
A. BCG EBF > MF EBF > MF 
HEU 
(EBF vs. MF) 
Week 14 A. SEB EBF > MF 
All EBF 
(6 vs. 14 Weeks) 
HEU A. BCG 6 > 14 Weeks 
HU A. BCG 6 > 14 Weeks 
All MF 




6 > 14 Weeks 
6 > 14 Weeks 
6 > 14 Weeks 




6 > 14 Weeks 
6 > 14 Weeks 
14 > 6 Weeks 
6 > 14 Weeks 
Red highlights indicate week 6 
Blue highlights indicate week 14 
Green highlights indicate evolution of CD4 and CD8 responses from 6 to 14 weeks of life.
HEU=HIV exposed uninfected; HU= HIV unexposed
 Comparing all Exclusively Breastfed (EBF) only; HEU vs. HU 
 Comparing all Mixed fed (MF) only; HEU vs. HU
 Comparing EBF vs. MF considering HEU & HU Infants separately
 Within EBF only  comparing 6 vs. 14 Weeks











Appendix C: Flow cytometric analysis of CD8- (CD4+) and CD8+ T cells 





Figure C1. Flow cytometric analysis of CD8- (CD4+) and CD8+ T cells proliferation measured by Ki67 
incorporation and cytokine in a whole blood intracellular staining assay. Gating strategy from a representative 
HEU infant whole blood stimulated with SEB for 6 days. A. From left to right, time gates for including consistent 
fluorescence over acquisition time and exclusion of doublets using forward scatter-area and forward scatter-height 
A. 
B. 
BI~ laser- Ki67 
File 
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(exclusion of compromised cells) 
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n 28.2 
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parameters in a singlets gate. B. From left following arrow, exclusion of compromised cells using keeper gates, 
exclusion of dead cells [violet viability dye positive cells (VIVID+)] gating live CD3+ cells and gating CD8-(CD4+) 











Appendix D: The number of HEU and HU infants whose CD4+ and CD8+ 
T cell responses to the different antigens was performed. 
Out of the 46 participants analyzed per group (i.e. HEU versus HU infants), 3 HEU versus 1 HU 
at six weeks and 6 HEU versus 4 HU at fourteen weeks infant samples were rejected by the rule 
(section 3.2.1.1 sub 1) (i.e. back ground responses were greater than those of the positive control) 
and recorded as negative. The remaining positive samples spread out within the different 
antigens studied (Table D1) were further analyzed as in section 3.2.1.1 above.   
Table D1: The number of HEU and HU infants whose CD4+ and CD8+ T cell responses to the different 
antigens was performed. Parameters include the different vaccine antigens Mycobacterium bovis bacillus 
Calmette-Guérin (BCG), Bordetella pertussis (BP) and tetanus toxoid (TT), and a superantigen Staphylococcal 
enterotoxin B (SEB), the time points 6 and 14 weeks and CD4+ and CD8+ T cells types for which responses 
(proliferation and cytokine production) were measured in HEU versus HU infants with their respective p-values. 
Adjustment for multiple comparisons was done using the Holm step-down approach(Columb et al.,, 2006) (see table 
2.2). Red highlights; represent p-values (and adjusted p-values) that remain significant after adjustment for multiple 
comparisons.   
Antigen Time point T Cell type HEU HU 
BCG 6 Weeks CD4+ 22 31 
CD8+ 22 31 
14 Weeks CD4+ 15 39 
CD8+ 15 39 
BP 14 Weeks CD4+ 23 30 
CD8+ 23 33 
TT 14 Weeks CD4+ 4 34 
CD8+ 3 33 
SEB 6 Weeks CD4+ 25  38 
CD8+ 25 38 
14 Weeks CD4+ 25 44 
CD8+ 25 44 
BCG 6 Weeks CD4+ 30 33 
CD8+ 27 24 
14 Weeks CD4+ 33 29 
CD8+ 34 25 
BP 14 Weeks CD4+ 4 7 
CD8+ 4 13 
TT 14 Weeks CD4+ 3 7 
CD8+ 3 11 
SEB 6 Weeks CD4+ 27 33 
CD8+ 32 32 
14 Weeks CD4+ 27 33 
CD8+ 28 32 
BCG 6 Weeks CD4+ 27 32 
CD8+ 29 29 
14 Weeks CD4+ 35 28 
CD8+ 37 25 
BP 14 Weeks CD4+ 3 9 
CD8+ 3 14 


























CD8+ 3 6  
SEB 6 Weeks CD4+ 25 30  
CD8+ 26 29  
14 Weeks CD4+ 26 34  
CD8+ 28 34  
BCG 6 Weeks CD4+ 28 34  
CD8+ 29 32  
14 Weeks CD4+ 35 29  
CD8+ 37 26  
BP 14 Weeks CD4+ 3 8  
CD8+ 3 11  
TT 14 Weeks CD4+ 3 5  
CD8+ 3 7  
SEB 6 Weeks CD4+ 25 32  
CD8+ 29 32  
14 Weeks CD4+ 26 33  
CD8+ 27 34  
BCG 6 Weeks CD4+ 22 26  
CD8+ 23 25  
14 Weeks CD4+ 32 27  
CD8+ 34 24  
BP 14 Weeks CD4+ 3 5  
CD8+ 3 10  
TT 14 Weeks CD4+ 3 6  
CD8+ 3 11  
SEB 6 Weeks CD4+ 27 28  
CD8+ 28 30  
14 Weeks CD4+ 26 31  











Appendix E: The median background response to evaluate the level of non-
specific stimulation in the assay. 
We had to determine the validity of our assay and ensure background responses were not high. 
The results showed that the whole blood assay (WBA) was valid for the measurement of immune 
responses to other antigens, and that there was little background.  
SEB- (positive control) and BCG- (vaccine with known immunogenicity) induced T cell
proliferation was valid as observed in the significantly higher CD4+ [Both SEB and BCG: 6 and
14 weeks (p<0.0001)] (Figure E1 and E2) and CD8+ [Both SEB and BCG: 6 and 14 weeks 
(p<0.0001)] (Figure E1 and E2) compared with the low back ground media alone T-cell
responses after antigenic stimulation at 6 and 14 weeks of age. 
A. SEB causes T-cell proliferation
(a) SEB - CD4+ (6 and 14 weeks)
(b) SEB – CD8+ (6 and 14 weeks)
Figure E1: Magnitude of SEB induced CD4+/CD8+ T cells proliferation at 6 and 14 weeks. Infants express a 
significantly higher SEB-induced (a) CD4+ and (b) CD8+ proliferation at 6 weeks and 14 weeks of life; p<0.05 











B. BCG causes T-cell proliferation
(a) BCG - CD4+ (6 and 14 weeks)
(b) BCG – CD8+ (6 and 14 weeks)
Figure E2: Magnitude of BCG induced CD4+/CD8+ T cells proliferation at 6 and 14 weeks. Infants have a












Appendix F: Co-linearity of birth weight and weight at 6 weeks. 
From the Kruskal Wallis test below, it is clear that weight at birth and at 6 weeks are not 
collinear and are significantly different (p=0.0001). 
. kwallis  birthweight, by(week6weight) 
Kruskal-Wallis equality-of-populations rank test 
+---------------------------+ 
week6w~t  Obs  Rank Sum 
----------+-----+---------- 
3230 9   3073.50  
3500 4   1822.00  
3650 4 300.00  
3670 4 58.00  
3730 5 15.00  
----------+-----+---------- 
3810 2 18.00  
3860 2 167.00  
3870 2 330.00  
3880 7 875.00  
3910 7   1029.00  
----------+-----+---------- 
3940 5   1570.00  
3960 8 876.00  
4010 9 961.00  
4020 5 497.50  
4060 4 500.00  
----------+-----+---------- 
4120   11   1548.50  
4130 4    106.00  
4150 7 696.50  
4190 9 238.50  
4210 5 375.00 
----------+-----+---------- 
4230 7 385.00  
4240 9   4563.00  
4250 4   2214.00  
4270 2 458.00  
4290 4 966.00  
----------+-----+---------- 
4320   11   1610.00  
4340 8   2904.00  
4360 5   3015.00  
4390 8   1576.00  
4400   10   2079.00 
----------+-----+---------- 
4420 6   1374.00  
4450 8   3876.00  
4460 9   2087.00  
4480   13   4423.00  












4510 2 110.00  
4520 8   1576.00  
4530   12   3404.00  
4550 6   1884.00 
4560 8   3644.00  
----------+-----+---------- 
4580 6   2601.00  
4600   19   7364.00  
4630   11   1435.00  
4640   15   6010.00  
4650 7   1029.00  
----------+-----+---------- 
4660 7   1029.00  
4670 9   5427.50  
4680   11   1609.50  
4700   18   8153.00 
4720 3   1213.50  
----------+-----+---------- 
4730 5   2022.50  
4740 2 53.00  
4750 5   2867.50  
4800   10   5229.00  
4810   15   8655.50  
----------+-----+---------- 
4820   12   6990.00  
4830 5   3142.50  
4850 5   1707.50 
4860   26  10342.50  
4870 9   2304.00  
----------+-----+---------- 
4880 7   1921.50  
4890 5   2022.50  
4900 5   2990.00  
4910   15   8130.00  
4930   16   5273.00  
----------+-----+---------- 
4960   18  10231.00  
5000 2 628.00  
5010   24  11839.00 
5020 2   1014.00  
5030   13   7802.50  
----------+-----+---------- 
5050 6   3042.00  
5060 4 660.00  
5080 2    585.00  
5100   16   2988.00  
5130   13   8320.00  
----------+-----+---------- 
5170 5   3515.00  
5200 7   5187.00 
5210 5   2867.50  
5230   10   6910.00  
5250 4   2374.00  
----------+-----+---------- 
5270   20   7212.50  
5280 6   3891.00  
5290 8   4588.00  
5300 6   1755.00  
5360 2   1280.00  
----------+-----+---------- 











5470 5   3200.00 
5500   25  17349.50  
5550 7   4585.00  
5560 8   6388.00  
----------+-----+---------- 
5590 8   3236.00  
5600 4   1366.00  
5610 5   1570.00  
5620 8   5384.00  
5630 6   4335.00  
----------+-----+---------- 
5650 6   3276.00 
5670 4   2890.00  
5680 5   3365.00  
5770 8   5384.00  
6200 9   7038.00  
----------+-----+---------- 
6760 8   6324.00  
+---------------------------+ 
chi-squared =   669.260 with 100 d.f. 
probability = 0.0001 
chi-squared with ties =   669.886 with 100 d.f. 
probability = 0.0001 
but that they are correlated: 
spearman week6weight birthweight 
 Number of obs = 802 
Spearman's rho =       0.6546
Test of Ho: week6weight and birthweight are independent
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